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1. Abbreviations 
 
ApoE:   apolipoprotein E 
BrdU:    5’-bromo-2’-deoxyuridine 
HCD:    high cholesterol diet 
HDC:    L-histidine decarboxylase 
HDL:    high density lipoprotein 
H1R:    histamine H1 receptor 
H2R:    histamine H2 receptor 
EC:    endothelial cell 
E-sel:    E-selectin 
IFNγ:    interferon gamma 
IL:    interleukin 
JNK:    c-jun N-terminal kinase 
LDL:    low density lipoprotein 
LDLr:    low density lipoprotein receptor 
LOX-1:   lectin-like oxLDL receptor-1  
L-sel:    L-selectin 
MCP-1 (CCL2):  monocyte chemoattractant protein-1 
mmLDL:   minimally modified low density lipoprotein 
NFκB:   nuclear factor-kappa B 
oxLDL   oxidized low-density lipoprotein 
PDGF:   platelet-derived growth factor 
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PECAM-1 (CD31):  platelet/endothelial cell adhesion molecule-1 
P-sel:    P-selectin 
RANTES (CCL5): regulated upon activation normal T-cell expressed 
and secreted (chemokine (C-C motif) ligand 5) 
ROS    reactive oxygen species 
SR-A:    scavenger receptor-A 
TF:    tissue factor 
Th:    T-helper 
VCAM-1:   vascular cell adhesion molecule-1 
VSMC :   vascular smooth muscle cell 
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2. Summary 
 
Atherosclerosis is a progressive inflammatory disease, resulting from 
elevated blood cholesterol level and/or other risk factors such as 
hypercholesterolemia, arterial hypertension, diabetes mellitus, cigarette smoking, 
obesity, and aging. Endothelial cell (EC) dysfunction, arterial accumulation of 
modified lipoprotein particles, and activation of the immune system are important 
hallmarks of atherosclerosis. Development of atherosclerotic plaques leads to 
narrowing of blood vessels, reduced arterial blood flow and, as a result, life-
threatening clinical complications like myocardial infarction or cerebral stroke.  
In this study, we reveal several new mechanisms regulating 
atherosclerotic plaque formation using mouse models of atherosclerosis. 
 
2.1 “Histamine H1 receptor promotes atherosclerotic lesion formation by 
increasing vascular permeability for low density lipoproteins” 
Histamine (2-[4-imidazole]-ethylamine) is an endogenous amine, the 
product of L-histidine decarboxylation. Histamine is a well known mediator of 
inflammation and allergic responses. Most of the pro-inflammatory actions of 
histamine are mediated via the H1 receptor (H1R) and activation of nuclear 
factor-kappa B (NFκB). Interestingly, histamine was demonstrated to modulate 
several processes potentially important for the development of atherosclerosis.  
 In order to investigate the role of histamine signalling in atherogenesis, we 
used both a pharmacological and a genetic approach. Apolipoprotein E deficient 
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mice (ApoE-/-), a widely used model of atherogenesis, were treated for 12 weeks 
with high cholesterol diet (HCD, Clinton-Cybulski diet, 1.25% cholesterol) and, in 
parallel, either with the H1R antagonist mepyramine or the H2R antagonist 
ranitidine. Moreover, we compared ApoE / H1R double mutants (ApoE-/- H1R-/-) 
and ApoE / H2R double mutants (ApoE-/- H2R-/-) to ApoE-/- mice after 12 weeks of 
HCD. 
 We observed that ApoE-/- animals treated with mepyramine, but not 
ranitidine, exhibited significantly reduced aortic plaque area compared with 
placebo-treated mice. Similarly, ApoE-/- mice genetically deficient in H1R, but not 
H2R displayed a 60% decrease in aortic plaque formation. Plasma cholesterol 
and triglyceride levels were not affected by the absence of H1R. In contrast, 
aortic permeability to 125I-low density lipoproteins (125I-LDL) was decreased in 18 
week old ApoE-/- H1R-/- animals, both with and without a HCD. Consistent with 
this observation, bone marrow transplantation revealed that the presence of H1R 
on vascular cells determined plaque formation.  
Lack of H1R resulted in decreased accumulation of lipids as well as 
macrophages and T-helper (Th) cells in atherosclerotic plaques. Moreover, 
reduced blood lymphocyte number and spleen size as well as decreased 
production of splenic Th1-specific cytokines were observed under these 
conditions. However, the reduced inflammation in ApoE-/- H1R-/- mice occurred 
secondary to alterations of the vessel wall, since bone marrow transplantation 
demonstrated that the development of atherosclerotic plaques did not depend on 
the presence or absence of H1R on bone marrow-derived cells. 
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 Thus, the H1R promotes atherosclerosis by increasing arterial lipoprotein 
permeability, while the presence of the H1R on bone marrow-derived cells does 
not influence plaque formation. 
 
2.2 “Accelerated early atherosclerosis in mice deficient in L-selectin” 
L-selectin (L-sel) is a member of the selectin family of adhesion 
molecules. It is ubiquitously expressed in leukocytes and mediates the initial 
attachment of leukocytes to activated endothelium as well as lymphocyte homing 
to peripheral lymphoid tissues. Recently, it has been demonstrated that the 
leukocyte-endothelium interaction during atherogenesis is, at least partially, L-sel 
dependent.  
To investigate the role of L-sel in atherosclerosis development in vivo, we 
generated double mutant ApoE / L-sel (ApoE-/- L-sel-/-) mice. These animals, 
together with the corresponding ApoE-/- controls, were fed a HCD for a time 
period of 6 or 12 weeks. In addition, we compared 6 month old ApoE-/- to ApoE-/- 
L-sel-/- mice without HCD. 
We found that deletion of L-sel accelerated early, but not advanced, 
atherosclerosis. Plasma lipid profile was not affected by the absence of L-sel. 
The extent of leukocyte capture and rolling in atherosclerotic aorta in vivo did not 
depend on of the presence of L-sel. In line with this, the cellular composition of 
atherosclerotic plaque was similar in all groups of animals. There was also no 
difference in aortic expression of cytokines. The lack of L-sel affected leukocyte 
distribution in all monitored groups; the lymph nodes were significantly smaller 
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and exhibited reduced cellularity, whereas the spleens were larger as compared 
to ApoE-/- controls. Moreover, ApoE-/- L-sel-/- mice exhibited increased blood 
leukocyte number.  
Thus, L-sel protects from early, but not advanced, atherosclerosis; this 
effect does neither depend on plasma lipids nor leukocytes-blood vessel 
interactions. 
 
2.3 “Endothelial overexpression of lectin-like oxidized low-density 
lipoprotein receptor-1 (LOX-1) increases LDL uptake and plaque formation” 
ECs dysfunction is known to be a key process in early atherosclerosis. 
Increased permeability, expression of adhesion molecules, and endothelial-
specific cytokines considerably accelerate the development of the disease. 
Lectin-like oxLDL receptor-1 (LOX-1) is postulated to be the main oxLDL 
scavenger receptor expressed by ECs. However, the role of LOX-1 in EC 
activation during atherogenesis is not well understood. 
To address this issue, we have generated transgenic mice overexpressing 
LOX-1 specifically in ECs. We fed these animals and the corresponding wild-type 
controls with a HCD for 30 weeks to investigate the role of LOX-1 in early 
atherosclerosis. We also crossbred LOX-1 transgenic (LOX-1 TG) animals with 
ApoE-/- mice to monitor the role of endothelial-specific LOX-1 overexpression in 
more advance stages of the disease. 
LOX-1 overexpression in ECs resulted in accelerated atherogenesis in 
both wild-type and ApoE-/- mice, which was associated with impaired EC-
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dependent relaxation to acetylcholine. Further, LOX-1 TG mice exhibited 
increased expression of adhesion molecules and enhanced accumulation of 
leukocytes in atherosclerotic plaques. Plasma lipids were similar in all groups of 
animals. 
These results indicate that the expression of LOX-1 by ECs is an 
important factor promoting atherogenesis. 
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2a. Deutsche Zusammenfassung der Doktorarbeit 
 
Die Arteriosklerose ist eine chronische inflammatorische Erkrankung, 
welche oftmals aus einem erhöhten Cholesterin Plasma Level resultiert. Die zur 
Entwicklung dieser Erkrankung beitragenden Risikofaktoren beinhalten unter 
anderem Hypercholesterinämie, Hypertonie, Diabetes, Rauchen, Übergewicht 
und Alter. Kennzeichen der Arteriosklerose sind Endothelzellen (EC)-
Dysfunktion, arterielle Anhäufungen von modifizierten Lipoprotein-Partikeln und 
Aktivierung des Immunsystems. Die Entwicklung von arteriosklerotischen 
Plaques führt zu einer Verengung der Blutgefässe, einem reduzierten arteriellen 
Blutfluss und lebensbedrohenden klinischen Folgeschäden wie beispielsweise 
Herzinfarkt oder Schlaganfall. 
In dieser Studie zeigen wir mittels Arteriosklerose-Mausmodellen mehrere 
neue Mechanismen, die bei der Entstehung von arteriosklerotischen Plaques 
bedeutsam sind, auf. 
 
2.1a “Histamin H1 Rezeptor fördert die arteriosklerotische Plaque Bildung 
durch erhöhte vaskuläre Permeabilität für Lipoproteine niederer Dichte” 
Histamin (2-[4-Imidazol]-Ethylamin) ist ein endogenes Amin und das 
Produkt der L-Histidin Decarboxylierung. Des Weiteren ist Histamin ein 
bekannter Mediator von Entzündungs- und Allergiereaktionen. Die meisten der 
proinflammatorischen Wirkungen von Histamin werden über den H1 Rezeptor 
(H1R) und die Aktivierung des Nukleären Faktors κB (NFκB) vermittelt. 
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Interessanterweise wurde gezeigt, dass Histamin mehrere potentiell für die 
Entwicklung der Arteriosklerose wichtige Prozesse reguliert. 
 Um die Rolle der Histamin-vermittelten Signalwirkung in der 
Arteriosklerose zu untersuchen, haben wir sowohl einen pharmakologischen wie 
auch einen genetischen Ansatz angewendet. Apolipoprotein E Knock-out Mäuse 
(ApoE-/-), ein bekanntes Modell der Arteriosklerose, wurden mit einer 12-
wöchigen Hoch-Cholesterin Diät (HCD, Clinton-Cybulski Diät, 1.25% Cholesterin) 
und parallel dazu entweder mit dem H1R Antagonisten Mepyramin oder dem H2 
Rezeptor (H2R) Antagonisten Ranitidin behandelt. Des Weiteren wurden ApoE / 
H1R Doppel-Knock-out Mäuse (ApoE-/- H1R-/-) und ApoE / H2R Doppel-Knock-
out Mäuse (ApoE-/- H2R-/-) mit ApoE-/- Mäusen nach der 12-wöchigen HCD 
verglichen. 
 Wir haben beobachtet, dass ApoE-/- Tiere, die mit Mepyramin behandelt 
wurden, signifikant weniger arteriosklerotische Plaques als die mit Placebo oder 
Ranitidin behandelten Mäuse aufwiesen. Zudem resultierte die genetische H1R, 
nicht aber H2R, Defizienz in ApoE-/- Mäusen in einer um 60% verminderten 
Atherom Entstehung. Der Lipidgehalt im Plasma wurde durch das Fehlen des 
H1R dagegen nicht beeinträchtigt. Im Gegensatz dazu war die Durchlässigkeit 
der Gefässwand für 125I-LDL in 18-wöchigen ApoE-/- H1R-/- Tieren vermindert, 
sowohl in solchen mit als auch in solchen ohne HCD. Übereinstimmend mit 
diesen Beobachtungen deckte eine Knochenmarktransplantation auf, dass die 
Präsenz des H1R auf Zellen der Gefässwand für die Ausbildung von 
arteriosklerotischen Plaques bedeutsam ist. 
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 Das Fehlen des H1R resultierte in reduzierter Akkumulation von Lipiden 
und auch Makrophagen sowieT-Helfer Zellen (Th) in den arteriosklerotischen 
Plaques. Des Weiteren wurde in der Abwesenheit des H1R eine Verminderung 
der Lymphozyten im Blut, der Milzgrösse sowie der Produktion der Th1-
spezifischen Cytokine beobachtet. Die geringere Endzündungsreaktion in ApoE-/- 
H1R-/- Mäusen trat sekundär zur Änderung der Gefässwand auf, weil die 
Knochenmarktransplantation aufzeigte, dass die Entwicklung von 
arteriosklerotischen Plaques nicht von der Anwesenheit oder Abwesenheit des 
H1R auf Zellen, die vom Knochenmark stammen, abhängt. 
 Wir kamen zum Schluss, dass der H1R die Entwicklung von 
arteriosklerotischen Plaques über eine erhöhte Durchlässigkeit der Blutgefässe 
für LDL fördert, während die Anwesenheit des H1R auf Zellen, die vom 
Knochenmark stammen, die Entwicklung von arteriosklerotischen Plaques nicht 
beeinflusst.  
 
2.2a “Beschleunigte frühe Arteriosklerose in L-Selektin Knock-out Mäusen” 
L-Selektin (L-sel) ist ein Mitglied der Familie der Selektin Adhäsions-
Moleküle. Es wird ubiquitär in Leukozyten exprimiert und vermittelt sowohl die 
anfängliche Anhaftung von Leukozyten zur Aktivierung des Endothels als auch 
das Lymphozyten-Homing zum periphereren Lymph-Gewebe. Kürzlich wurde 
gezeigt, dass die Interaktion zwischen Leukozyten und Endothel während der 
Entstehung der Arteriosklerose, zumindest teilweise, L-sel abhängig ist.  
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Um die Rolle von L-sel in der Entstehung der Arteriosklerose in vivo zu 
untersuchen, haben wir ApoE / L-sel Doppel-Knock-out Mäuse (ApoE-/- L-sel-/-) 
generiert. Diese Tiere, zusammen mit den entsprechenden ApoE-/- Kontrollen, 
wurden während 6 oder 12 Wochen einer HCD unterzogen. Zusätzlich haben wir 
halbjährige ApoE-/- Mäuse mit gleich alten ApoE-/- L-sel-/- Tieren, die nicht einer 
HCD unterzogen wurden, verglichen. 
Wir haben herausgefunden, dass die genetische Defizienz von L-sel die 
frühe, jedoch nicht die späte Arteriosklerose beschleunigt. Der Lipidgehalt im 
Plasma wurde durch das Fehlen von L-sel nicht beeinträchtigt. Zudem war das 
Ausmass des Leukozyten Einfangens und Rollens in der arteriosklerotischen 
Aorta in vivo unabhängig von der Präsenz von L-sel. Übereinstimmend mit 
diesen Beobachtungen wurde gezeigt, dass die zelluläre Zusammensetzung der 
arteriosklerotischen Plaques in sämtlichen Tiergruppen ähnlich war. Es gab auch 
keinen Unterschied in der Expression von Cytokinen in der Aorta. Die Absenz 
von L-sel beeinflusste wie erwartet die Leukozyten Verteilung in allen 
beobachteten Gruppen. Zudem waren die Lymphknoten signifikant kleiner und 
wiesen eine reduzierte Zellularität auf und die Milz war grösser als diejenige der 
ApoE-/- Kontrollen. Des Weiteren wiesen ApoE-/- L-sel-/- Mäuse eine erhöhte 
Anzahl von Leukozyten im Blut auf. 
Demzufolge schützt L-sel vor der frühen, aber nicht vor der späten 
Arteriosklerose. Dieser Effekt hängt weder von den Lipiden im Plasma noch von 
der Leukozyten-Blutgefäss Interkation ab. 
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2.3a “Die Überexpression von LOX-1 im Endothel erhöht die Aufnahme von 
LDL und die Plaque Bildung“ 
Als ein entscheidender Prozess in der frühen Arteriosklerose hat sich die 
EC-Dysfunktion erwiesen. Erhöhte Durchlässigkeit, Expression von 
Adhesionsmolekülen und Endothel-spezifische Cytokine beschleunigen die 
Krankheitsentwicklung beträchtlich. LOX-1 gilt als der hauptsächliche oxLDL 
Scavenger Rezeptor, der von EC exprimiert wird. Jedoch ist die Rolle von LOX-1 
in der Aktivierung der EC und der Entwicklung der Arteriosklerose noch nicht 
vollständig bekannt.  
Um diese Frage anzugehen, haben wir transgene Mäuse generiert, die 
LOX-1 spezifisch in EC überexprimieren. Wir haben diese Tiere sowie die 
entsprechenden Wildtypen einer 30-wöchigen HCD unterzogen, um die Rolle 
von LOX-1 in der frühen Arteriosklerose zu untersuchen. Zudem haben wir LOX-
1 transgene (LOX-1 TG) Tiere mit ApoE-/- Mäusen gekreuzt, um die Endothel-
spezifische LOX-1 Überexpression während späteren Stadien der Krankheit zu 
studieren.  
Die Überexpression von LOX-1 in EC resultierte in einer beschleunigten 
Arteriosklerose Entwicklung, sowohl in Wildtypen als auch in ApoE-/- Mäusen, 
was einer verminderten EC-abhängigen Relaxation auf Acetylcholin nahesteht. 
Zudem zeigten LOX-1 TG Mäuse eine erhöhte Expression von 
Adhesionsmolekülen sowie eine Anhäufung von Leukozyten in 
arteriosklerotischen Plaques. Der Lipidgehalt im Plasma war ähnlich in allen 
Tiergruppen. 
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Unsere Resultate deuten darauf hin, dass die Expression von LOX-1 in 
EC ein wichtiger Faktor der Arteriosklerose Entwicklung ist. 
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3. Introduction 
 
Complications of atherosclerosis are the leading cause of death in 
Western societies (Fig. 1). Atherosclerosis is a progressive inflammatory disease 
characterized by accumulation of cells, lipids, and extracellular matrix in the 
vessel wall eventually leading to narrowing of vessels and clinical manifestations 
like myocardial infarction or cerebral stroke. Endothelial dysfunction, LDL 
oxidation, and leukocyte accumulation are key events in atherosclerosis [1-3]. 
Although our knowledge of the pathophysiology of this disease has improved 
substantially over the last years, molecular events occurring in the pathogenesis 
of atherogenesis are still poorly understood.  
 
 
 
 
 
 
 
 
Figure 1 
Complications of atherosclerosis are the main cause of death in developed countries; 
adapted from National Vital Statistics Reports, USA, 2003.  
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3.1 Risk factors 
Epidemiological studies reveal that complications of atherosclerosis are 
responsible for the majority of deaths in developed countries.  
Endothelial dysfunction is an early event in atherogenesis. The healthy 
endothelium helps to maintain integrity of blood vessel, regulates vasomotion, 
and actively inhibits thrombosis and inflammation. Thus, factors that injure ECs 
contribute to the development of the disease. Several risk factors, such as 
hypercholesterolemia or homocysteinemia, have been identified for causing 
endothelial dysfunction.  
Typical Western diet, rich in triglycerides and cholesterol, is undoubtedly 
one of the reasons of increased prevalence of the disease [1]. Indeed, a large 
body of evidence points to hypercholesterolemia as one of the most serious risk 
factors for the development of atherosclerosis [4]. It has been demonstrated that 
an increased risk of coronary artery disease correlates with elevated plasma 
cholesterol levels. Especially dangerous are high LDL plasma levels, the major 
transporter of cholesterol in the blood stream [5, 6]. Accumulation of LDL in the 
arterial intima followed by subsequent oxidation and acetylation are key events in 
formation of atherosclerotic plaques, a hallmark of atherosclerosis [1].  
 Also individuals suffering from hypertension are more prone to 
development of atherosclerosis, coronary artery disease, and stroke [6]. Other 
factors associated with endothelial dysfunction predisposing to atherosclerosis 
are diabetes, aging, and cigarette smoking [6-9]. 
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3.2 Pathogenesis of atherosclerosis 
 
3.2.1 Fatty streak formation 
The intima, composed of a single layer of endothelium and underlying 
connective tissue, maintains integrity of the blood vessel [10]. Early 
atherosclerosis is characterized by the accumulation of LDL in the arterial intima, 
occurring secondary to activation of EC and increased permeability of the vessel 
wall. Factors modulating vascular permeability, such as histamine, have been 
implicated in atherosclerosis, but their in vivo studies relevance is unclear [11, 
12]. 
Hypercholesterolemia is a major risk factor predisposing to fatty streak 
formation [4]. Indeed, the stimulation of endothelial LOX-1 in vitro with LDL 
results in cell activation [13]. It remains to by clarified, whether this process 
affects atherosclerosis development in vivo.  
LDL accumulated in the vessel wall become eventually modified by 
reactive oxygen species (ROS) and 15-lipoxygenase or other enzymes first to 
minimally modified LDL (mmLDL) and then to oxidized LDL (oxLDL) [14]. mmLDL 
is a potent chemoattractant molecule, which further accelerates formation of 
atherosclerotic changes. Accumulation of oxLDL in the vessel wall accounts for 
the formation of the earliest morphological manifestation of atherosclerosis - the 
fatty streak [1, 15]. 
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Some of the main risk factors associated with atherosclerosis like 
hypertension, diabetes or cigarette smoking exert their negative effects primarily 
via activation of the endothelium [7, 8, 16]. 
 
3.2.2 Attraction of leukocytes 
Under normal conditions, ECs resist prolonged contact with blood 
leukocytes. However, when activated, both ECs and leukocytes start to express 
adhesion molecules thus facilitating attachment and migration of cells into sites 
of inflammation [10]. The recruitment of leukocytes is regulated by different 
families of adhesion molecules. Expression of particular adhesion molecules and 
their interaction with ligands regulates the specificity of leukocyte migration into 
the arterial wall [1, 17]. The initial phase of an inflammatory response is 
characterized by the slowing down of leukocytes, which allows their firm 
adhesion and transmigration. The molecules responsible for initial rolling and 
tethering of leukocytes are called selectins [17, 18]. The selectin family of 
adhesion molecules consists of E-selectin (E-sel), P-selectin (P-sel), and L-sel. 
E-sel and P-sel mediate the attachment of leukocytes to the endothelial layer 
before firm adhesion mediated via integrins, vascular cell adhesion molecule-1 
(VCAM-1), and platelet/endothelial cell adhesion molecule (PECAM-1) occurs 
(Fig. 2) [17, 18]. The importance of E-sel and P-sel in atherosclerosis in vivo was 
demonstrated with genetically modified mice; in contrast the role of L-sel remains 
to be clarified.  In addition, expression of several chemoattractant proteins 
enhances accumulation of leukocytes in atherosclerotic plaques. Mouse models 
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show that the presence of certain molecules like chemokine (C-C motif) ligand 5 
(CCL5), interferon gamma (IFNγ), monocyte chemoattractant protein-1 (MCP-1), 
and IL-8 is important for leukocyte transmigration into sites of inflammation [1]. 
 
 
 
 
 
 
 
 
Figure 2 
Rolling and tethering of leukocytes along activated endothelium is mediated primarily via 
the selectin family of adhesion molecules. Arrestment and transmigration occur due to 
interactions of integrins with their ligands expressed by ECs; adapted from Blankenberg 
et al [17]. 
 
3.2.3 Formation of an atherosclerotic plaque 
Macrophages express several scavenger receptors specific for modified 
LDL such as scavenger receptor A (SR-A) or CD36. Although these two together 
mediate the uptake of the majority of cholesterol, their role in atherosclerosis 
development remains controversial [19, 20]. 
Once transmigrated to the arterial intima, macrophages start to scavenge 
oxLDL particles and undergo morphological changes to become foam cells, the 
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hallmark of early atherosclerotic lesions. Foam cells express several 
proinflammatory molecules like tissue factor (TF), platelet-derived growth factor 
(PDGF), several cytokines, metalloproteinases, and produce ROS, all of which 
contribute to attract other leukocytes, stimulate vascular smooth muscle cell 
(VSMC) migration, and exacerbate inflammation [1]. 
 Following transmigration of monocytes, a subsequent key step in 
atherogenesis is accumulation of lymphocytes. T cells are relatively low in 
number, but represent a very important component of the atherosclerotic plaque 
[21]. Several animal studies emphasize the importance of lymphocytes, in 
particular Th CD4+ cells in atherogenesis [2, 21, 22]. Indeed, deficiency of 
adaptive immunity leads to reduced atherosclerosis in mice lacking ApoE, 
whereas reconstitution of immuno-deficient mice with CD4+ T cells accelerates 
atherogenesis [21, 22]. 
  Both activated endothelium and lipid loaded foam cells express PDGF, a 
potent attractant of and mitogen for VSMCs. Progression of atherosclerotic lesion 
formation is associated with migration of VSMCs from the media to the activated 
intima. VSMCs not only secrete large amounts of connective tissue into the 
plaque, but can also scavenge modified LDL particles and become foam cells 
[23] (Fig. 3). 
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Figure 3 
Formation of advanced atherosclerotic plaque; adapted from Stevens et al [24]. 
 
3.2.4 Complications of atherosclerosis 
Formation of fibrous plaques with a central necrotic core, which may 
eventually lead to clinical complications, is a typical feature of advanced 
atherosclerosis. Unlike fatty streaks, an advanced atherosclerotic plaque can be 
easily visualized macroscopically. It is composed of a fibrous cap containing 
extracellular connective tissue matrix and VSMCs as well as lipid core containing 
mainly foam cells, cholesterol crystals, and cellular debris [1]. Progression of 
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plaque development is associated with narrowing of the vessel lumen (stenosis) 
and reduced blood flow. This can result in ischemic injury of the organ supplied 
by the diseased vessel [25]. 
Thickness and composition of the fibrous plaque are critical determinants 
of plaque stability. Substantial lipid core and thin fibrous cap are typical features 
of unstable plaques. In contrast, thick fibrous cap and relatively small lipid core 
are more characteristic of stable plaques. Rupture of unstable plaques is a very 
common complication of atherosclerosis. It results in exposure of TF-rich plaque 
components to the blood stream and leads to thrombosis and eventually vessel 
occlusion [26] (Figure 3). Rupture of atherosclerotic plaques may have different 
clinical manifestations depending on the vessel localization, for example stroke if 
plaque rupture occurs in the vessel supplying the brain, or myocardial infarction if 
plaque rupture occurs in the coronary circulation. In addition, fragments of 
disrupted atherosclerotic lesions may embolize to distal sites [25]. 
Development of late stages of atherosclerosis is associated with 
weakening of the vessel wall and loss of elastic tissue leading to localized, blood-
filled dilations called aneurysms. Aneurysm formation affects most often the 
abdominal portion of the aorta, the blood vessels supplying the brain (circle of 
Willis), and other large arteries. Rupture of the aneurysm leads to internal 
bleeding and is a serious life threatening condition [27]. 
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3.3 Role of histamine in atherogenesis 
Rozenberg, I., Tanner, FC, Luescher, TF. 2008. Histamine. In Cardiovascular 
hormone systems, from molecular mechanism to novel therapeutics. M. Bader, 
editor. Weinheim: Wiley-Blackwell. 295-314. 
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1. Introduction 
 
Due to its numerous effects and possible therapeutic potential, histamine is one of 
the most intensely studied mediators in medicine. Histamine is an endogenous 
amine produced in a one step reaction from L-histidine. It regulates vasoreactivity, 
coagulation as well as immunological responses. An increased production of 
histamine has been noted during allergic action, within atherosclerotic plaques, in 
patients with stable coronary artery disease, and in patients with acute coronary 
syndromes [1-3]]. Most of the histamine is released by activated mast cells and 
basophils, but also by macrophages, lymphocytes, platelets, and other cells [3-8]. 
Mast cells store histamine in secretory vesicles and only release it upon stimulation 
with specific ligands (i.e. IgE) activating surface receptors. Degranulation of mast 
cells causes fast, but transient increases in histamine concentration, resulting in 
hypersensivity, vascular permeability, vasodilation, or vasoconstriction [9]. 
Recently, it has been demonstrated that the histamine-producing enzyme, L-
histidine decarboxylase (HDC), is expressed in activated macrophages from human 
atherosclerotic plaques. Since macrophages, unlike mast cells, do not contain 
secretory vesicles, macrophage-derived histamine is not stored, but rather produced 
de novo [10, 11]. Therefore, macrophage stimulation does not cause sudden 
increases in local histamine concentration, but rather provides persistently increased 
histamine tissue levels.  
The diverse effects of histamine are due to differential expression and regulation of 
the four histamine receptors (see Section 3). 
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2. Biochemistry  
 
2.1 Synthesis: 
Histamine (2-[4-imidazole]-ethylamine) is an endogenous amine, the product of L-
histidine decarboxylation. Its synthesis is controlled primarily by the availability of L-
histidine and the activity of HDC [12], the rate limiting enzyme controlling histamine 
biosynthesis (Figure 2.1.1). Activity of HDC is regulated mainly at the transcriptional 
level, at least in cultured enterochromaffin-like cells [13, 14]. The enzyme has been 
detected in various cells of the immune system, gastrointestinal and bronchial 
endocrine cells, neuroendocrine cells, as well as some tumor cells [15]. Histamine 
may be released in response to various immunological (immunoglobulin E, 
cytokines) and non-immunological (compound 48/80, calcium ionophore, opioids) 
stimuli.  
 
 
Figure 2.1.1 Biosynthesis of histamine from L-histidine. 
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2.2 Degradation: 
In order to avoid excessive inflammatory reactions, histamine’s action has to be 
highly regulated by limited production but also degradation. Histamine inactivation 
occurs either through metabolization into inactive compounds and/or cellular uptake. 
Indeed, many cells express high affinity receptors specific for monoamines like 
histamine. One recently characterized receptor is the organic cation transporter 
(OCT)-2. On the other hand, histamine is inactivated is by two catabolic pathways: 
(i) methylation by histamine N-methyltransferase (HNMT) and (ii) oxidative 
deamination by diamine oxidase. Since histamine cannot easily enter cells and 
HNMT seems to be localized primarily in the cytoplasm, there are two hypotheses of 
histamine metabolization: the transporter hypothesis and the membrane hypothesis. 
The transporter hypothesis assumes that histamine is transported via special 
histamine transporters into the intracellular space, where it is metabolized by HNMT. 
According to the second hypothesis, HNMT upon stimulation is translocated to the 
plasma membrane, where it has easy access to histamine [16]. 
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3. Receptors 
 
The pleiotropic and tissue-specific effects of histamine are mediated via four G-
coupled protein membrane receptors (histamine H1-H4 receptors; Table 3.1). 
Effects of histamine upon histamine receptor ligation are very complex and often 
contradictory; depending on the pattern of receptors it activates [17].  
 
 Table 3.1 Expression and function of histamine receptors. 
Type of 
receptor 
Expression 
Molecular pathway 
involved 
Function 
Histamine 
H1 
receptor 
EC, SMC, leukocytes, 
nerve cells 
phospholipase C via 
Gq/11 family of G 
proteins 
allergy and 
inflammation 
Histamine 
H2 
receptor 
EC, VSMC, leukocytes, 
gastric parietal cells, 
nerve cells 
couple to adelylyl 
cyclase via GTP-
binding protein Gs 
gastric acid 
secretion, 
inflammation 
Histamine 
H3 
receptor 
neurons, leukocytes 
inhibition of cAMP via 
Gi/o 
neurotransmission
Histamine 
H4 
receptor 
leukocytes, nerve cells 
inhibition of cAMP via 
Gi/os 
allergy and 
inflammation 
 
Histamine H1 receptor is coupled to the Gq/11 protein and the phosphoinositol 
hydrolysis pathway resulting in enhancement of inflammatory processes. Its 
activation induces signs of allergic reactions, such as bronchoconstriction, increased 
vascular permeability, and vasodilation due to nitric oxide (NO) release from 
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vascular endothelial cells (ECs). Mice lacking the histamine H1 receptor develop 
normally, but exhibit behavioral changes, such as reduced exploratory behavior and 
altered circadian rhythm as well as increased daily food intake [18]. These 
observations confirm the importance of histamine HI receptor signaling in the brain. 
Histamine H1 receptor deficiency also attenuates airway allergic inflammation, which 
is associated with decreased levels of T-helper 2 cells (Th2), cytokine production, 
and circulating IgE in bronchoalveolar lavage fluid [19]. 
The histamine H2 receptor is coupled to the Gαs protein and cAMP signaling. Acting 
via the H2 receptor, histamine regulates inflammatory responses, angiogenesis, and 
gastric acid secretion. Homozygous mutant mice lacking histamine H2 receptor are 
viable and, surprisingly, exhibit normal basal gastric pH. This observation is clearly 
distinct from the elevated gastric pH observed in mice treated with H2 receptor 
antagonists [20].  
The histamine H3 receptor has been detected in the central as well as peripheral 
nervous system and negatively regulates the release of histamine and other 
neurotransmitters as well. Mice treated with histamine H3 receptor antagonists 
exhibit behavioral changes, such as enhanced spatial learning and reduced anxiety. 
A study with H3 receptor knockout animals as well as with H3 receptor agonist 
treated animals demonstrated a role of H3 receptor in energy homeostasis and 
suggested a therapeutic potential for H3 receptor ligands in the treatment of obesity 
and diabetes mellitus [21]. The recently discovered histamine H4 receptor involves 
Gi/os protein signaling and enhances intracellular Ca2+ levels. Activation of histamine 
H4 receptor stimulates accumulation of inflammatory cells, primarily eosinophils and 
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mast cells, and activates proinflammatory responses. H4 receptor-deficient mice as 
well as mice treated with H4 receptor antagonist exhibit diminished allergic 
pulmonary inflammation, decreased infiltration of lung eosinophils and lymphocytes, 
and decreased Th2 responses [22]. 
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4. Vasomotion 
 
The role of histamine in the regulation of vasomotion is complex and varies 
depending on its concentration and the receptor it activates. Both the contracting 
and the relaxing responses in bronchial arteries are significantly inhibited by 
mepyramine, suggesting that the H1-receptor is involved [23]. In contrast, another 
study demonstrated that H2 receptor activation is crucial for NO production and 
vascular relaxation in human arteries and veins [24]. Hence, the involvement of 
histamine receptors in vasomotion regulation is complex. Evidence indicates that the 
vasodilator response is related to the release of NO from ECs, and that the 
vasoconstrictor effect is resulting from a direct action of histamine on vascular 
smooth muscle cells (VSMCs). Indeed, histamine-dependent arterial dilation, but not 
constriction, is blunted in mice lacking endothelial nitric oxide synthase (eNOS, also 
classified as NOSIII) [25]. However, contraction of VSMCs cells triggered by 
histamine can be at least in part endothelium-dependent due to the action of 
endothelium-derived contracting factor (EDCF). It has been proposed that 
stimulation with low concentrations of histamine results in relaxation of human 
vessels, whereas higher concentrations exert an opposite effect [26]. Importantly, 
the action of histamine differs depending on the vascular bed involved. In mammary 
artery, it induces endothelium-dependent relaxation, whereas it promotes contraction 
in saphenous vein (Figure 4.1) [27]. 
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Figure 4.1 Dual role of histamine in regulation of vascular tone. Histamine acting via 
histamine H1 receptor (H1R) increases eNOS activity and enhances NO production 
in ECs through increasing intracellular Ca2+ levels. Release of NO from EC causes 
relaxation of VSMCs. Concomitantly, histamine-triggered release of EDCF from ECs 
may cause contraction of VSMCs. 
 
4.1 EDRF 
In the past, VSMCs were considered to be the sole regulator of vascular tone. 
VSMCs, the most abundant component of the vessel wall, are indeed known to 
contain large numbers of contractile proteins, determining the resistance of vessels 
and therefore regulating blood flow. However, in 1980, Furchgott and Zawadzki 
observed that anatomical integrity of the EC layer is crucial for acetylcholine-
mediated relaxation of VSMCs [28]. This observation proved the importance of the 
endothelium in the vasoconstriction-vasodilatation balance. The compound 
discovered in 1980 was initially, based on its function, named endothelium-derived 
relaxing factor (EDRF) and later characterized as NO [29]. Since this discovery, 
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various endothelium-derived vasodilators (prostacyclin) and vasoconstrictors 
(endothelin-1, angiotensin II, prostaglandins) have been identified as well. Together 
with NO, these compounds contribute to the regulation of vascular tone [30]. 
Histamine plays a role in endothelial NO release, thereby promoting vasodilation. 
NO dilates blood vessels by stimulating soluble guanylyl cyclase and increasing 
cGMP in VSMCs [31, 32]. NO is synthesized from L-arginine by at least three 
distinct NOS isoforms. Production of NO in ECs is regulated by the constitutively 
expressed eNOS. In response to stimuli such as shear stress, acetylcholine, or 
histamine, eNOS activity and NO production in ECs increases.  
In addition to its vasoactive properties, NO also prevents platelet aggregation and 
leukocyte adhesion as well as VSMC proliferation, which may be relevant in the 
development of cardiovascular diseases like atherosclerosis [33-35]. The importance 
of NO release by ECs in blood pressure regulation has been confirmed with eNOS 
deficient animals, which develop hypertension [36]. It has also been reported, that 
NO production is diminished in patients with elevated blood pressure when 
compared to normotensive individuals [37].  
 
4.1.1 Signaling Role of Ca2+ 
Production of NO is regulated primarily by modulation of eNOS activity in a Ca2+-and 
calmodulin-dependent manner. After synthesis eNOS is translocated to specialized 
signal-transducing plasmalemmal compartments called caveolae. Caveolin, the main 
structural component of caveolae, interacts with eNOS leading to enzyme inhibition. 
It has been demonstrated in human ECs that the inhibitory action of calveolin on 
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eNOS activity is modulated by Ca2+/calmodulin. Addition of calmodulin indeed 
disrupts the eNOS-calveolin complex in a Ca2+ dependent manner [38].  
H1 receptor stimulation results in activation of phospholipase C and the production 
of inositol-1,4,5-triphosphate from phosphatidylinositol (4,5)-bisphosphate, which 
triggers the release of Ca2+. Accordingly, histamine increases eNOS activity and 
enhances NO production at least in part through increase of intracellular Ca2+ [39].  
 
4.1.2 Activation of eNOS  
Phosphorylation represents a crucial post-translational regulatory mechanism of 
enzyme activation. In case of eNOS, phosphorylation on serine or tyrosine residues 
is probably involved in intracellular enzyme translocation followed by its activation. 
Interestingly, histamine-mediates eNOS phosphorylation at serine 1177, 
independent of Ca2+ signaling. It has been shown, that inhibition of protein kinase A 
as well as 5’-AMP-activated protein kinase (AMPK) strongly inhibits phosphorylation 
and activation of eNOS triggered by histamine stimulation [40].  
 
4.1.3 Transcriptional Regulation of eNOS  
Regulation of gene expression is a very common way to modulate biological 
pathways. Recently, it has been shown that histamine does not only play a role in 
activation of eNOS, but also affects the expression level of the enzyme. Indeed, 
histamine upregulates gene expression of endothelial nitric oxide synthase in 
cultured human ECs in a Ca2+-dependent manner. The enhanced expression of 
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eNOS could be prevented by mepyramine, a selective antagonist of histamine H1 
receptor, but not by histamine H2 and histamine H3 receptor antagonists [41]. 
 
4.2 EDCF 
ECs can not only induce relaxation, but also contraction of underlying VSMCs. The 
molecule responsible for endothelium-dependent contraction was initially called 
EDCF. Indeed, various mediators produced by the endothelium such as endothelin-1 
or thromboxane A2 were later found to induce vascular constriction. It has been 
demonstrated that histamine may trigger either constriction or relaxation depending 
on its concentration and the animal model used. The histamine-mediated 
constriction of VSMCs was blocked by histamine H1 receptor inhibitors, but 
increased after application of histamine H2 receptor inhibitors in a canine model [42]. 
Similarly, histamine induced strong constriction in rabbit basilar artery [43]. These 
results suggest that histamine, activating the H1 receptor, plays a role in 
endothelium-derived contraction, presumably via the generation of EDCF, which can 
be modulated by the concomitant release of endothelium-derived NO via activation 
of the H2 receptor. 
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5. Thrombosis 
 
Coronary atherosclerosis complicated by plaque rupture and thrombosis is primarily 
responsible for the development of acute coronary syndromes. Under normal 
conditions, however, the endothelial layer provides a barrier between the blood and 
the vessel wall; it maintains blood fluidity and is crucial for regulating the interaction 
between blood and solid tissue components. Hence, ECs are able to prevent 
procoagulant and thrombotic events. They synthesize negatively charged heparin 
sulfate proteoglycans (glycocalix), maintaining the vascular wall in an antithrombotic 
state by accelerating the inhibition of factor Xa and thrombin via antithrombin III. ECs 
are also the main source of tissue factor pathway inhibitor (TFPI). Binding of TFPI to 
activated factor Xa leads to the formation of an inactive tissue factor-VIIa-Xa 
complex. Furthermore, the endothelium expresses the receptor for thrombomodulin, 
which modifies thrombin specificity and accelerates thrombin mediated conversion of 
precursor protein C to activated protein C. Finally, the sequestration of two 
prothrombotic molecules - tissue factor as well as von Willebrand factor (vWF) 
accounts for the antithrombotic properties of ECs. Under certain conditions like 
inflammatory stimulation, however, ECs participate in activation of coagulation. Mast 
cells, the main source of histamine, tend to redistribute and accumulate at sites of 
thrombosis. Histamine indeed promotes a series of prothrombotic events like 
activation of ECs, induction of tissue factor expression, and stimulation of vWF 
release. Furthermore, histamine is released by platelets during thrombotic events, 
and exogenous histamine dose-dependently enhances platelet aggregation induced 
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by various stimuli. Conversely, it has been demonstrated that mast cell-deficient 
mice are hyperresponsive to thrombogenic stimuli, probably due to lack of mast cell-
derived heparin [44].  
 
5.1 Tissue Factor Expression 
Tissue factor is a 263-residue membrane bound glycoprotein, member of the type II 
cytokine receptor family, controlling initiation of the extrinsic coagulation cascade, 
since it is the cellular receptor for activated factor VII. The endothelial layer provides 
a barrier between the blood and the tissue factor-rich vessel wall, which prevents 
thrombotic events. However, upon stimulation with pro-inflammatory agents like 
tumor necrosis factor alpha (TNFα), CD40 ligand (CD40L), interleukin-1 beta (IL-1β), 
or histamine, ECs express tissue factor, resulting in activation of the coagulation 
cascade. Tissue factor, by inducing coagulation, seems to be involved in the 
pathogenesis of atherosclerosis and the initiation and propagation of acute coronary 
syndromes as well [45]. Elevated tissue factor level and activity have indeed been 
detected in patients with unstable angina. Moreover, tissue factor is highly 
expressed in atherosclerotic plaques in numerous cell types including ECs, smooth 
muscle cells, and monocytes/macrophages [46, 47]. However, additional studies are 
required to elucidate the role of tissue factor in the development of atherosclerosis in 
vivo.  
Recently, it has been observed that histamine induces tissue factor expression in a 
concentration-dependent manner on both human ECs and VSMCs [48]. Histamine-
induced tissue factor expression is mediated by activation of the H1 receptor, since 
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H1 receptor antagonists prevent this effect. Although mRNA stability, intracellular 
storage and localization of tissue factor may significantly modulate its activity, tissue 
factor induction in response to inflammatory stimuli is predominantly regulated at the 
transcriptional level. Functional studies indicate that Sp1 controls basal tissue factor 
gene expression, while a promoter (-227 to -172) containing two AP-1 sites and an 
NF-kappa B site mediates induction of tissue factor mRNA in monocytes and ECs 
[49]. Accordingly, tissue factor is activated by several signal transduction pathways 
including mitogen-activated protein kinases (MAPKs), and protein kinase C. 
Consistent with these data, p38, extracellular signal-regulated kinase and c-Jun N-
terminal kinase inhibitors attenuate histamine-induced tissue factor expression, 
suggesting a crucial role of MAPK in this process (Figure 5.1.1) [48].  
 
Figure 5.1.1 Histamine and thrombosis. Histamine induces tissue factor expression 
on both human ECs and VSMCs via activation of MAPKs. This histamine effect is 
mediated by histamine H1 receptor (H1R). Tissue factor expression leads to 
coagulation cascade activation and eventually thrombus formation. ERK, 
extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; TF, tissue factor. 
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5.2 Weibel-Palade Bodies 
ECs contain rod-shaped storage vesicles called Weibel-Palade bodies (WPBs) 
harboring preformed vWF multimers and P-selectin. Stimulation of ECs with 
molecules raising intracellular Ca2+ levels like histamine or thrombin result in 
exocytosis of the WPB content to the EC surface (Figure 5.2.1). Histamine H1 
receptor, but not H2 receptor antagonists abolish this effect [50]. 
 
Figure 5.2.1 Histamine induces WPB release. Histamine induces exocytosis of 
endothelial WPBs in a Ca2+ - dependent manner. Released molecules like vWF, P - 
selectin (P-sel), IL–8 and endothelins (ET) modulate several important physiologic 
processes like inflammation, homeostasis and vasomotion. DAG, diacylglycerol; 
H1R, histamine H1 receptor; IP3, inositol-1,4,5-triphosphate; PIP2, 
phosphatidylinositol (4,5)-bisphosphate. 
 
Both vWF and P-selectin are known to play a crucial role in thrombus formation. 
vWF is a large glycoprotein stabilizing coagulation factor VIII and participating in the 
binding of activated platelets to exposed collagen through receptors such as 
glycoprotein Ib on the platelet surface. Deficiency or mutation of vWF causes von 
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Willebrand disease, which is characterized by an increased bleeding time [51]. In 
contrast, P-selectin is a member of the selectin adhesion molecule family, which 
mediates initial rolling and attachment of leukocytes to the activated endothelium 
promoting the development of inflammation [52]. Recent studies, however, reveal 
additional possible role of P-selectin in thrombus formation. Binding of P-selectin to 
P-selectin glycoprotein ligand-1 indeed mediates the interaction of platelets with the 
endothelium as well as interaction of platelets with leukocytes and other platelets, 
thereby enhancing thrombotic events. What is more, P-selectin has been reported to 
enhance the expression of tissue factor on cultured human monocytes [53]. 
Consistent with these observations, P-selectin-deficient mice exhibit an abnormally 
prolonged bleeding time and unusual thrombus geometry during ex vivo thrombus 
formation [54]. In contrast, transgenic animals having high soluble P-selectin level 
exhibit a pro-coagulant state [55]. In humans, elevated P-selectin level is associated 
with prothrombotic disorders such as stroke or peripheral artery disease [56].  
Hence, histamine induces a dose-dependent secretion of both vWF and P-selectin 
from WPBs, by a Ca2+ dependent mechanism, which can be blocked by 
mepyramine, a histamine H1 receptor antagonist. These observations strongly 
suggest a crucial role of histamine in thrombus formation by stimulating the release 
of WPBs. 
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5.3 Platelet aggregation 
When vessel integrity is compromised, activated platelets bind to exposed collagen 
and vWF to form a hemostatic plug stabilized by fibrin. Similar to mast cells and 
other inflammatory cells, platelets contain intracellular granules containing numerous 
inflammatory and thrombogenic mediators like histamine, platelet factor 4, platelet-
derived growth factor, ADP, and reactive oxygen species. Exposure of platelets to 
thrombin indeed results in aggregation and histamine release. The presence of 
histamine receptors on the platelet membrane, high activity of HDC, and the ability 
to take up preformed histamine suggest that histamine plays a role in platelet 
activation. Indeed, histamine enhances aggregation of isolated human platelets 
induced by a variety of agonists. The effect of histamine on platelet aggregation is 
abolished by H1 receptor, but not H2 receptor antagonists [57, 58]. On the other 
hand, histamine enhances eNOS activation resulting in endothelial NO production, 
which inhibits platelet activation and represents an important negative feedback 
mechanism [33, 35]. In conclusion, histamine plays a role not only in initiation of 
coagulation by stimulating tissue factor expression as well as WPBs release, but 
also regulates platelet aggregation during thrombus formation.  
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6. Inflammation  
 
Histamine is a well-known mediator of inflammation and allergic responses. 
Released from mast cells or macrophages during inflammatory processes, it can 
affect immune responses at several levels. Most of the proinflammatory actions of 
histamine are mediated via the H1 receptor and activation of MAPKs as well as 
NFκB [59]. In contrast, the immunoregulatory effects of histamine are primarily 
mediated via the H2 receptor [60].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Histamine and inflammation. Histamine modulates expression of several 
proinflammatory molecules by different types of cells–monocyte/macrophages (M), 
Th1, Th2, ECs and VSMCs. E/sel. E-selectin; IFN, interferon; MMP, matrix 
metalloproteinase. 
 
Histamine modulates progression of inflammation at many levels. It increases 
vascular permeability, enhances adhesion molecule expression, probably plays a 
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role in activation of monocytes/macrophages, modulates the Th1 versus Th2 
response, and the production of pro- as well as anti-inflammatory cytokines. (Figure 
6.1) [15]. 
 
6.1 Vascular Permeability 
An increased permeability leading to tissue edema and accumulation of leukocytes 
is a hallmark of inflammation. Similarly, early atherosclerosis is characterized by the 
accumulation of low density lipoproteins in the arterial intima, occurring secondary to 
increased EC permeability. Histamine, acting via both H1 receptor and H2 receptor, 
is one of the most important regulators of this process. It has been observed that 
histamine causes transient phosphorylation of myosin light chains, actin 
cytoskeleton rearrangement, and intracellular gap formation in ECs occurring in a 
Ca2+-dependent manner, which leads to increased vascular permeability [61, 62]. 
Inhibition of the MAPK kinase 1/2 with a specific peptide inhibitor significantly 
attenuates the histamine mediated changes in venular permeability [63].  
 
6.2 Adhesion Molecule Expression 
Under normal conditions, the endothelial layer resists prolonged contact with blood 
leukocytes. Upon activation, however, ECs start to express molecules, which 
facilitate firm adhesion and extravasation of leukocytes into sites of inflammation. 
This process is regulated by different families of adhesion molecules expressed on 
both, leukocytes and ECs. The types of adhesion molecules and their interaction 
regulate the specificity of leukocyte migration into tissues. The selectin family of 
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adhesion molecules (E-, P-, and L-selectin) mediates the initial attachment of 
leukocytes to the endothelial layer before firm adhesion mediated via integrins, 
vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 
(ICAM), and platelet EC adhesion molecule-1 (CD31) occurs. Genetic deletion of 
either E-selectin, P-selectin, or VCAM-1 significantly diminishes the formation of 
atherosclerotic lesions. Histamine, acting via H1 receptor and NFκB, enhances IL-4 
and TNFα-mediated expression of VCAM-1, TNFα- mediated expression of E-
selectin and ICAM-1, as well as surface translocation of P-selectin in human ECs in 
vitro [64, 65]. These observations suggest that histamine plays an important role in 
regulating adhesion of leukocytes to the activated endothelium. Indeed, in a rat 
model, histamine induces rolling of polymorphonuclear cells in a P-selectin 
dependent manner, which is almost completely abolished by H1 receptor, but not H2 
receptor blockade [66, 67]. 
 
6.3 Leukocyte Accumulation 
Leukocyte accumulation is controlled by chemoattractant molecules and adhesion 
molecules, and represents an important process in atherosclerosis, leading to 
plaque progression. Adherent leukocytes enter the intima by diapedesis. Histamine 
enhances expression of several chemoattractant cytokines such as monocyte 
chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) [68, 69]. In vivo studies 
demonstrate the importance of these molecules: mice lacking MCP-1 or its receptor- 
chemokine (C-C motif) receptor 2 exhibit a striking decrease in mononuclear 
phagocyte accumulation and atherosclerotic plaque development. 
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6.4 Regulation of Th1/Th2 Balance 
Many inflammatory processes are associated with accumulation of CD4+ T cells 
subsets. Stimulated by antigen, CD4+ T cells can differentiate into two types of 
effector cells, namely Th1 and Th2. In general, Th1 cells activate 
monocytes/macrophages and induce B cells to produce IgG antibodies; in contrast 
Th2 cells initiate the humoral immune response by activating naive antigen-specific 
B cells to produce IgM antibodies. The immune responses enhancing Th1 effector 
mechanisms are considered to be pro-atherogenic. Th1 and Th2 cells exhibit 
differential expression of histamine receptors - Th1 cells preferentially express H1 
receptor, whereas Th2 cells show predominant expression of H2 receptor. 
Stimulation of Th1 cells, but not Th2 cells, with histamine results in increased 
intracellular calcium level, translocation of NF-AT, and activation of IL-2. Indeed, 
histamine enhances CD3-induced proliferation of Th1 cells and blocks proliferation 
of Th2 cells. This effect of histamine is abolished by H1 receptor or H2 receptor 
blockers, respectively. T cells lacking the H1 receptor exhibit significant suppression 
of interferon-γ secretion, enhancement of Th2 cytokine production - IL-4 and IL-13 - 
and reduction of T-cell proliferation. In contrast, T cells lacking H2 receptor exhibit 
significant enhancement of both Th1- and Th2-specific cytokines [60]. These 
observations suggest that histamine can modulate T cell-mediated immune 
responses and thereby the development of atherosclerosis and other diseases. 
 
 
 
Rozenberg et al: Histamine 
 
 XXVI
6.5 Macrophage Activation 
Macrophage-derived foam cells are one of the most abundant components of 
atherosclerotic plaques. Foam cells do not only scavenge modified low-density 
lipoprotein particles rich in cholesterol, but also express many proinflammatory 
molecules. Monocytes switch their receptor expression profile from H2 receptor to 
H1 receptor upon stimulation, suggesting that histamine signaling may influence the 
transition from monocytes to activated macrophages [70]. Moreover, histamine, 
acting via the H2 receptor, enhances expression of lectin-like oxidized low-density 
lipoprotein receptor-1 (LOX-1), which scavenges modified lipoprotein particles, and 
that of the chemoattractant MCP-1, thereby possibly enhancing both macrophage 
accumulation and foam cell formation [71]. Accordingly, histamine mediated 
upregulation of both LOX-1 and MCP-1 is abrogated in activated macrophages 
which express predominantly H1 receptor. 
 
6.6 Obesity 
Obesity is an important risk factor for the development of cardiovascular diseases. 
Obesity is regulated by both, environmental and genetic factors. Leptin, the product 
of the ob gene, exerts wide-ranging effects including food intake and energy 
expenditure. Consistently, disruption of leptin protein or leptin receptor leads to the 
development of obesity. Interestingly, hypothalamic neuronal histamine contributes 
to the leptin signaling pathway via the H1 receptor. Indeed, mice with targeted 
deletion of H1 receptor exhibit a disrupted diurnal feeding rhythm, increased food 
consumption, and with time develop obesity [18]. In contrast, H2 receptor blockers 
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improve excess weight in patients with type 2 diabetes mellitus as well as in patients 
treated with anti-psychotic drugs [72]. 
Rozenberg et al: Histamine 
 
 XXVIII
7. Atherosclerosis 
 
Complications of atherosclerosis are the leading cause of death in Western 
societies. Atherosclerosis is a progressive inflammatory arterial disease 
characterized by accumulation of lipids and leukocytes, proliferation of VSMCs, and 
excessive production of extracellular matrix. The first stage of atherosclerosis 
development is characterized by activation of the endothelial layer lining the blood 
vessels, leading to functional activation, increased permeability and recruitment of 
leukocytes. The first cells found in the intima are macrophages, which scavenge 
oxidized low density lipoproteins leading to lipid loaded foam cell formation. Foam 
cells express numerous cytokines, metalloproteinases, and reactive oxygen species, 
which all promote development of inflammation and progression of atherosclerosis. 
Advanced plaques with a necrotic core composed of monocytes, foam cells, and 
lipids as well as a fibrous cap consisting of connective tissue is a hallmark of 
advanced atherosclerosis leading to narrowing of the vessel and clinical 
manifestations [73].  
Many cell types involved in development and progression of atherosclerosis, such as 
ECs, macrophages, mast cells, and VSMCs are able to produce histamine and 
express histamine receptors. Indeed, HDC, the rate limiting enzyme for histamine 
production, is highly upregulated in murine atherosclerotic lesions [3]. Moreover, 
numerous processes crucial for atherosclerosis development such as vascular 
permeability, adhesion molecules expression, leukocyte activation, and lipid 
metabolism are known to be affected by histamine. These observations strongly 
Rozenberg et al: Histamine 
 
 XXIX
suggest that histamine modulates the development and progression of 
atherosclerosis, and pharmacological or genetic blockade of histamine receptors 
may have beneficial effects in this context. 
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8. Autoimmune Diseases and Allergy 
 
8.1 Autoimmune Diseases 
The incidence of autoimmune diseases has increased significantly during the last 
years in developed countries. The reason for this phenomenon, however, is not 
clear. Under normal conditions, the immune system is able to distinguish between 
self components and external pathological antigens since self-tolerance is controlled 
by clonal selection of T and B cells during their maturation. Autoimmune disease 
occurs when this normal state of self-tolerance is altered, for example, when antigen 
is not abundant/organ specific, or not expressed in thymus, or when tolerance to an 
abundant antigen is broken. Autoimmune diseases result from a disrupted balance 
between anti- and pro-inflammatory signaling. Hence, degranulation of mast cells 
and the resulting increase in plasma histamine levels has been reported during the 
development of autoimmune diseases [74, 75]. Indeed, due to its modulating effect 
on immune responses, histamine receptors are interesting targets in therapy of 
autoimmune diseases. 
 
8.2 Allergy 
Histamine is an important mediator of allergic disease, as it is mainly stored in mast 
cells and basophils. Allergic reactions can be induced when allergens cross-link IgE 
bound to the Fc RI receptor on mast cells, but several other stimuli such as 
cytokines and complement components can induce activation of mast cells as well. 
Activated mast cells are involved in inflammation by secreting molecules stored in 
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their granules such as histamine as well as by producing cytokines and leukotrienes. 
The release of inflammatory mediators, cytokines, and chemokines at sites of 
allergic reactions results in the recruitment of eosinophils and basophils. Overall, 
leukocyte activation provokes a variety of inflammatory symptoms from sneezing 
and a running nose to life threatening bronchoconstriction, hypotension and shock 
depending on the dose of allergen and the route of entry. The inflammatory reaction 
triggered by mast cell activation can be classified as an immediate response, 
occurring within minutes after mast cell activation, and a late-phase response lasting 
hours or days. Degranulation of mast cells leading to the release of histamine, 
prostaglandins, and other molecules enhancing vascular permeability, and inducing 
inflammation is a main mediator of the immediate response. The late phase 
response is generated via production of proinflammatory cytokines, chemokines, 
and leukotrienes.  
During experimental asthma, allergic rhinitis, and in patients with urticaria, histamine 
level is significantly higher when compared with healthy subjects. Indeed, it has 
been demonstrated that histamine is affecting both immediate and late phase 
allergic responses [1, 76]. 
 
8.2.1 Immediate Response  
Mast cells and basophils are the main sources of stored histamine. Activation of 
these cells results in degranulation and a sudden transient increase in histamine 
concentration. Hence, release of stored histamine from these cells accounts for 
histamine mediated immediate allergic reactions. Acting via the H1 receptor, 
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histamine increases vascular permeability leading to edema, bronchoconstriction, 
and mucus production. These alterations result in the development of typical allergic 
symptoms such as bronchial obstruction, sneezing, rhinitis, and itching. Consistent 
with the pathological role of the H1 receptor, administration of histamine H1 receptor 
blockers is known to have beneficial effects on such responses.  
 
8.2.2 Long-Term Response 
Histamine is also involved in the regulation and modulation of long-term 
inflammatory responses. Recent studies demonstrate that macrophages and 
neutrophils are the main source of inducible histamine. Many cell types involved in 
the development of allergic responses are known to express histamine receptors on 
their surface. Neutrophils and eosinophils express both H1 receptor and H2 
receptor, whereas basophils express predominantly H2 receptor. In contrast to the 
immediate response, where histamine promotes the allergic reaction, late allergic 
response mediated by basophils and neutrophils is rather attenuated by histamine. 
Indeed, histamine, acting via H2 receptor, suppresses leukotriene synthesis [77]. 
This observation confirms the ambiguous role of histamine in the development of 
inflammation and allergy.  
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9. Conclusions  
Histamine is an endogenous amine produced in a one step reaction from L-histidine. 
Activity of HDC, a rate limiting enzyme crucial for histamine formation, is detected in 
many different cell types including various cells of the immune system, 
gastrointestinal and bronchial endocrine cells, neuroendocrine cells, as well as some 
tumor cells.  
Histamine mediates several processes like homeostasis, vasomotion, and 
inflammation crucial for normal organism function. The action of histamine depends 
on several factors such as its concentration, the type of receptor it activates, and the 
vascular bed it acts on.  
 Elevated plasma and/or tissue histamine levels are often associated with 
pathogenesis of cardiovascular, allergic, and autoimmune diseases. Indeed, 
histamine is known to modulate numerous processes such as vascular permeability, 
adhesion molecule expression, and leukocyte activation, which are crucial for the 
development of atherosclerosis, allergy, or autoimmune disease. Therefore, 
pharmacological or genetic blockade of histamine receptors, for some of these 
disorders, represent a well established, for others a promising therapy. 
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3.4 Role of L-selectin in atherogenesis 
Atherosclerosis is a chronic inflammatory disease resulting from 
accumulation of cholesterol and leukocytes into the arterial intima. Several 
molecules regulate extravasation of inflammatory cells. Multiple studies indicate 
that the initial phase of this process is mediated primarily by the selectin family of 
adhesion molecules [18, 28-30]. Indeed, it was demonstrated in vivo that the 
capture and rolling of leukocytes along activated endothelium are severely 
compromised in animals lacking either of the selectins [28, 30-32].  
L-sel is expressed ubiquitously by most leukocytes, where it serves 
adhesive as well as signaling functions [33, 34]. Like other members of the 
selectin family, L-sel contains an extracellular region that includes a C-type lectin 
domain, an epidermal growth factor like domain, and short consensus repeat 
units homologous to domains found in complement-binding proteins [35].  
Molecules such as c-jun n-terminal kinase (JNK) and NFκB influence a 
variety of pro-atherogenic processes, such as EC activation, T-cell differentiation, 
proliferation, and migration of VSMCs. It has been described that mice lacking 
JNK-2 show decreased atherosclerosis due to reduced oxLDL uptake by 
macrophages [36]. L-sel does not only play an important role in leukocyte homing 
and extravasation, but it is also involved in the regulation of signal transduction 
via its cytoplasmic domain. Indeed, ligation of L-sel with a specific antibody or 
ligand elicits a number of intracellular events including activation of JNK, NFκB, 
as well as protein kinase C, and leads to leukocyte activation [33, 34]. 
  29
The ligands of L-sel vary depending on the vascular bed and the type of 
blood vessel. Recently, it has been proposed that activated endothelium lacks 
functional L-sel ligand [37]. Instead, L-sel exerts its physiological functions due to 
its interaction with P-sel glycoprotein ligand-1 expressed by the leukocytes. This 
finding emphasizes the importance of secondary capture resulting from 
leukocyte-leukocyte interaction [38].  
L-sel mediates interactions of lymphocytes with high endothelial venules 
of peripheral lymph nodes which are crucial for lymphocyte homing and 
activation, and it is required for the initial stages of leukocyte extravasation into 
sites of inflammation. Indeed, mice lacking L-sel exhibit drastically reduced 
lymphocyte homing to peripheral lymph nodes as well as significantly reduced 
leukocyte capture and rolling across activated endothelium [18, 28, 38]. 
Moreover, it has been demonstrated that lymphocyte recruitment into the aortic 
wall during atherosclerosis development is partially L-sel dependent [39].  
Although the role of E- and P-sel in atherogenesis is well known [40], 
there are no in vivo studies addressing the role of L-sel in the development and 
progression of atherosclerosis in vivo. 
 
3.5 Role of lectin-like oxLDL receptor-1 in atherogenesis 
LOX-1, together with SR-A and CD36, belongs to the family of scavenger 
receptors [41]. Chemically, it is a type II glycoprotein with short cytoplasmic N-
domain, a transmembrane domain, and an extracellular lectin-like domain [13]. 
Homodimerisation of LOX-1 assures optimal ligand binding [42]. LOX-1 binds 
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several ligands including advanced glycation-end products, modified lipoproteins, 
apoptotic bodies as well as bacterial components. Expression of LOX-1 upon 
normal conditions is usually low and increases during pathological conditions like 
elevated blood pressure, diabetes, or atherosclerosis [43-45]. Several mediators 
such as oxLDL, angiotensin II, cytokines, sheer stress, and advanced glycation 
end-products have been shown to modulate LOX-1 expression [46-50]. Unlike 
SR-A and CD36, LOX-1 is the main scavenger receptor expressed by ECs [13, 
45]. In addition, several studies prove the presence of LOX-1 on 
monocytes/macrophages, VSMCs, and platelets (Fig. 4); under these conditions, 
however, its role seems to be secondary to that of other scavenger receptors 
[41]. 
Ligation of LOX-1 results not only in oxLDL uptake, but also in activation 
of molecular pathways leading to increased production of ROS, NFκB activation, 
and, as a result, ECs dysfunction [50, 51]. LOX-1-mediated signaling leads to 
increased production of adhesion molecules (E-sel, P-sel, and VCAM-1) and 
chemokines (MCP-1), which has been shown to be important for leukocyte 
migration into sites of inflammation [52-54]. LOX-1 ligation also leads to 
diminished NO production and increased metalloproteinase expression that 
promote EC dysfunction [55, 56]. Moreover, increased ROS release generates a 
positive feedback loop for further LDL oxidation. Indeed, it has been shown that 
mice lacking LOX-1 exhibit significant reduction in atherosclerotic plaque 
formation due to reduction in proinflammatory and prooxidant signals [57]. 
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Recent reports demonstrate the important role of LOX-1 in both early and 
advanced atherosclerosis. However, the relevance of endothelial LOX-1 in the 
pathogenesis of atherosclerosis remains unclear.  
 
 
 
 
 
 
 
 
 
 
Figure 4 
Expression of LOX-1 by cellular components of atherosclerotic plaque; adapted form 
Dunn et al [44]. 
 
  32
4 The goal of the study 
 
The aim of the study was to find and characterize new molecules relevant 
for atherosclerosis development. 
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5 Animal models used in the study 
 
5.1 Apolipoprotein E deficient mice 
Mice are the most commonly used model to study the causal relation 
between genes and the phenotype of human diseases. However, wild-type mice 
are resistant towards atherosclerosis development due to the very low levels of 
plasma LDL and relatively high levels of high density lipoproteins (HDL). 
Therefore, genetically modified animals have to be ussed. Developed in the 
laboratory of Dr. Nobuyo Maeda at The University of North Carolina, ApoE-
deficient mice are a widely used model of atherogenesis [58, 59]. ApoE is part of 
the LDL particle recognized by the LDL receptor (LDLr). Its deficiency 
significantly increases plasma LDL levels, whereas plasma HDL remains 
unchanged (Tab. 1) [60]. Thus, animals lacking a functional ApoE gene develop 
atherosclerosis spontanously starting from approximately the 3rd month of age 
[59].  
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 WT normal diet ApoE-/- normal diet ApoE-/- atherosclerotic diet
Number of mice 12 12 11 
Total cholesterol (mg/dl) 51.8 ± 6.2 142.2 ± 37.3* 359.9 ± 91.4* 
HDL cholesterol (mg/dl) 33.3 ± 6.0 29.9 ± 6.4 33.4 ± 12.4 
LDL cholesterol (mg/dl) 13.6 ± 5.4 101.2 ± 29.3* 318.2 ± 72.8* 
 
Table 1 
Plasma lipids in WT and ApoE-/- mice. Data expressed as mean ± SD. ApoE-/- normal vs. 
WT mice (*P<0.05), ApoE-/- atherosclerotic vs. normal diet mice and WT mice (*P<0.05), 
ApoE-/- normal diet vs. WT mice (*P<0.05); adapted from Guo et al [60]. 
 
5.2 Histamine H1 receptor and H2 receptor deficient mice 
H1R-/- mice have been developed by homologous recombination in 1996 
at the Department of Molecular Immunology at Kyushu University in Japan in 
order to study the effect of histamine signaling on behavior and activity. Indeed, 
animals lacking H1R exhibit significant impairment of locomotor and exploratory 
behavior. H1R deficient mice develop obesity starting from 48 weeks of age [61]. 
Moreover, these animals exhibit altered immunological response to various 
stimuli which make them very interesting targets to study in the context of 
atherosclerosis development [62, 63]. H2R-/- mice have been created in year 
2000 in the same laboratory to investigate the effect of histamine signaling on 
gastrointestinal functions. The study of Kobayashi et al. demonstrated that, 
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although histamine acting via H2R regulates gastric acid secretion, deletion of 
H2R does not impair secretion of gastric acid [64]. A later study showed that 
deletion of H2R results in attenuation of Th1 effector cell responses and 
susceptibility to experimental allergic encephalomyelitis [65]. 
 
5.3 L-selectin deficient mice 
Mice lacking L-sel have been generated by homologous recombination at 
the Department of Immunology of the Duke University, Medical Center Durham, 
North Carolina, USA, , to study the relevance of L-sel in leukocyte homing to 
peripheral lymph nodes, interactions between leukocytes and activated vascular 
endothelium, as well as leukocyte distribution. 
L-sel-/- mice are viable and fertile, however, they exhibit abnormal 
leukocyte distribution, as well as leukocyte rolling along activated endothelium 
[28]. 
 
5.4 Lectin-like oxLDL receptor-1 transgenic mice 
Transgenic mice overexpressing LOX-1 specifically in ECs were 
developed in our laboratory by Dr Alexander Akhmedov using the EC-specific 
Tie2 promoter. Here, we report for the first time the phenotype of these animals. 
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6. Summary of the results 
 
6.1 “Histamine H1 receptor promotes atherosclerotic lesion formation by 
increasing vascular permeability for low density lipoproteins” 
 
A) Pharmacological blockade or genetic deletion of H1R, but not H2R, decreases 
atherosclerosis development in ApoE-/- mice. 
B) Atherosclerotic animals lacking H1R exhibit decreased arterial permeability to 
LDL. 
C) Accumulation of lipids and leukocytes into atherosclerotic plaques is 
diminished in the absence of H1R. 
D) Spleen size and the number of blood lymphocytes are decreased in the 
absence of H1R. 
E) Production of Th1-specific cytokines: IL-2, IFNγ, and CCL5 (but not Th2-
specific cytokines: IL-4 and IL-10) is diminished in the spleen of ApoE-/- H1R-/- 
mice. 
F) H1R expressed on vascular cells determines the development of 
atherosclerosis. 
G) H1R expressed on bone-marrow derived cells does not affect atherosclerosis. 
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6.2 “Accelerated early atherosclerosis in mice deficient in L-selectin”  
 
A) Genetic deletion of L-sel increases early but not advanced atherosclerosis in 
ApoE-/- mice. 
B) L-sel deletion does not influence leukocyte capture and rolling along aorta 
during atherosclerosis development. 
C) L-sel deletion does not influence cellular composition of atherosclerotic plaque 
in ApoE-/- mice. 
D) L-sel deletion results in altered blood lymphocyte numbers in ApoE-/- mice. 
E) The presence of L-sel is necessary for maintaining proper leukocyte 
distribution within the body. 
 
6.3 “Endothelial overexpression of lectin-like oxidized low-density 
lipoprotein receptor-1 (LOX-1) increases LDL uptake and plaque formation” 
 
A) Endothelial-specific overexpression of LOX-1 results in accelerated 
atherosclerosis in both LOX-1 TG and LOX-1 TG/ApoE-/- animals.  
B) ECs overexpressing LOX-1 exhibit a significant increase in oxLDL uptake. 
C) Endothelial-dependent relaxation to acetylcholine is impaired upon LOX-1 
overexpression. 
D) Both LOX-1 TG and LOX-1 TG/ApoE-/- mice exhibit significantly increased 
expression of adhesion molecules. 
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E) LOX-1 TG animals exhibit a significant increase in accumulation of leukocytes 
into atherosclerotic plaques. 
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7. Publications that contributed to the work 
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“Histamine H1 receptor promotes atherosclerotic lesion formation by 
increasing vascular permeability for low density lipoproteins”. Manuscript 
submitted.  
 
Own contribution: 
1) Animal breeding, generation of ApoE-/- H1R-/- and ApoE-/- H2R-/- mice 
2) Animal experiments 
• Harvesting of the mice 
• En-face Oil-red O staining of aortas 
• Quantification of atherosclerosis 
3) Immunohistochemistry 
• Cryosection of aortic root, spleen and lymph node 
• Immunostainings  
• Analysis of immunostainings (AnalySIS-Five) 
4) FACS analysis of murine splenocytes (together with Pavani Mocharla) 
5) Isolation of mRNA and protein from mouse aorta and spleen 
6) qRT PCR 
7) Bone marrow transplantation (together with Janin Hofmann) 
8) Proliferation of VSMC in vivo, 5’-bromo-2’-deoxyuridine (BrdU) 
incorporation  
9) In vivo permeability assay using EBD and I125 LDL. 
Histamine H1 Receptor Promotes 
Atherosclerotic Lesion Formation by Increasing 
Vascular Permeability for Low Density Lipoproteins 
 
Izabela Rozenberg1,2, Lucia Rohrer2,3, Janin Hofmann4, Burkhard Becher4, Jorge Soliz5,  
Pavani Mocharla1,2, Alexander Akhmedov1,2, Jan Borén6, Jan Steffel1,2,7, 
Takeshi Watanabe8, Thomas F. Lüscher1,2,7, Felix C. Tanner1,2,7 
  
1 Cardiovascular Research, Institute of Physiology, University of Zurich 
2 Center for Integrative Human Physiology, University of Zurich 
3 Institute of Clinical Chemistry, University Hospital Zurich, Zurich 
4 Institute of Experimental Immunology, Dept. of Pathology, University Hospital Zurich 
5 Institute of Veterinary Physiology, Vetsuisse Faculty, Zurich, Switzerland 
6 Wallenberg Laboratory, Sahlgrenska Academy at Göteborg University, Goteborg, Sweden 
7 Cardiology, Cardiovascular Center, University Hospital Zurich, Zurich 
8 Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan  
 
Short title: Histamine in Atherosclerosis 
Total character count: 27’420 
 
Address for correspondence: 
Felix C. Tanner, MD 
Cardiovascular Research, Institute of Physiology, University of Zurich and Cardiology, 
Cardiovascular Center, University Hospital Zurich 
Winterthurerstrasse 190, CH-8057 Zurich, Switzerland 
Email: felix.tanner@access.uzh.ch 
Rozenberg et al: Histamine in atherosclerosis 
  II
Nonstandard abbreviations 
 
ApoE:    apolipoprotein E 
CCL5:    chemokine (C-C motif) ligand 5 
EBD:    evans blue dye  
HCD:    high cholesterol diet 
H1R:    histamine H1 receptor 
H2R:    histamine H2 receptor 
LDL:    low-density lipoprotein 
ORO:    oil red-o  
PFA:    paraformaldehyde 
SMa:    α-smooth muscle actin 
qRT PCT:   quantitative real time polymerase chain reaction 
VSMC:   vascular smooth muscle cell 
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Abstract 
 
Enhanced endothelial permeability with intimal accumulation of low density 
lipoproteins (LDL) stimulates the formation of atherosclerotic lesions. Histamine is 
known to increase vascular permeability. Here we demonstrate that ApoE-/- mice treated 
with a histamine H1, but not H2 receptor antagonist developed 40% less atherosclerotic 
lesions in the aorta than placebo treated controls. Similarly, genetic deletion of the H1, 
but not H2 receptor resulted in 60% reduction of lesions compared to ApoE-/- controls. 
The H1 receptor enhanced permeability for LDL and lipid accumulation in aorta, 
whereas plasma lipoprotein levels remained unaffected. In contrast, the H1 receptor did 
not affect proliferation and migration of vascular smooth muscle cells. Bone marrow 
transplantation confirmed that the formation of atherosclerotic lesions depended on the 
H1 receptor on vascular cells, while its presence on bone marrow-derived cells was 
irrelevant for plaque development. Mice expressing the H1 receptor exhibited higher 
levels of the chemokine CCL5 and higher numbers of macrophages and lymphocytes in 
plaques, higher numbers of circulating lymphocytes, and larger spleens. These 
observations indicate that H1, but not H2 receptor activation drives the formation of 
atherosclerotic lesions through an increased vascular permeability for LDL, which is 
associated with an enhanced secondary aortic and systemic inflammation. 
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Introduction 
 
Histamine (2-[4-imodazole]-ethylamine) is a biogenic amine involved in inflammatory 
responses and plays a dominant role in acute allergic reactions (1, 2). In this context, it 
increases vascular permeability resulting in the formation of erythema and edema. In the arterial 
system, histamine has been shown to participate in the response to acute injury by promoting 
arterial remodeling and enhancing neointima formation (3). There is increasing evidence that 
histamine may also modulate the response to chronic arterial injury such as atherosclerotic 
lesion formation (3-5). An enhanced vascular permeability is indeed an early alteration of arterial 
function during the formation of such lesions. This increase in permeability is an important 
prerequisite for the accumulation of low density lipoproteins (LDL) in the evolving lesions (6-8). 
Once LDL are present in the vessel wall, they become oxidized and thereby exhibit chemotactic 
and pro-inflammatory properties leading to monocyte accumulation, foam cell formation, and 
progression of lesion formation (9). However, whether histamine enhances vascular permeability 
in the setting of chronic arterial injury and whether such an effect would promote the formation of 
atherosclerotic lesions has not been examined yet. 
Histamine exhibits its actions through four G-protein coupled membrane receptors, of 
which the H1 and H2 receptor are expressed in the vessel wall (4). Most of the deleterious 
vascular effects of histamine such as vasospasm, tissue factor induction, and intimal thickening 
after acute arterial injury are mediated by the H1 receptor (3, 10-13); similarly, the increase in 
vascular permeability induced by histamine is mediated via this receptor (14, 15). These 
observations indicate an important role of the H1 receptor in the vascular response to acute 
injury. This study was therefore designed to investigate using a combined pharmacological and 
genetic approach whether (1) histamine promotes atherosclerotic lesion formation, (2) whether 
an increased vascular permeability is involved, and (3) whether these effects are mediated by 
the H1 receptor. 
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Results and Discussion 
 
Histamine H1 receptor promotes the formation of atherosclerotic lesions 
To assess the role of histamine receptor activation in the formation of atherosclerotic 
lesions, 6 week old mice were fed a high cholesterol diet for 12 weeks and treated with the H1 
receptor antagonist mepyramine or the H2 receptor antagonist ranitidine throughout this time 
period. Animals treated with mepyramine, but not ranitidine, exhibited a nearly 40% reduction in 
atherosclerotic lesions (mepyramine: p<0.05 vs. control; ranitidine: p=NS vs. control; Fig 1A and 
B). This observation was confirmed by a genetic approach involving ApoE / H1 receptor double 
knockout (ApoE-/-H1R-/-) and ApoE / H2 receptor double knockout (ApoE-/-H2R-/- ) animals. ApoE-
/-H1R-/- mice exhibited a 60% decrease in atherosclerotic lesions as compared to ApoE-/- controls 
(p<0.01; Fig 1C and D). In contrast, plaque formation in ApoE-/-H2R-/- mice did not differ from 
ApoE-/- controls (p=NS; Fig 1C and D). It is not surprising that genetic deletion of the H1 receptor 
had a more pronounced effect on plaque formation than pharmacological blockade, as this 
difference is consistent with the higher efficacy of the genetic as compared to the 
pharmacological approach. These observations demonstrate that activation of the H1 receptor, 
but not the H2 receptor, promotes the formation of atherosclerotic lesions. Hence, H1 receptor 
activation is involved in the vascular response to chronic injury. 
Plasma levels of cholesterol and triglycerides as well as the respective subfractions did 
not differ in ApoE-/-H1R-/- mice and ApoE-/- controls (p=NS; Tab 1), indicating that the effect of H1 
receptor activation does not depend on plasma lipoproteins. The H1 receptor thus modulates 
vascular lesion formation independent of changes in lipid metabolism. Although food intake was 
similar in the different groups of animals (Tab 1), ApoE-/-H1R-/- mice were slightly heavier than 
ApoE-/- controls, which may be related to the known reduced physical activity of ApoE-/-H1R-/- 
animals (16). However, the weight difference between the two groups of mice likely did not affect 
the formation of atherosclerotic lesions, since the heavier group would be expected to exhibit 
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more rather than less lesions (17). 
The expression of histidine decarboxylase, H1 receptor, and H2 receptor in mouse aorta 
was assessed using qRT-PCR. Histidine decarboxylase expression was 2.5-fold higher in aorta 
of atherosclerotic ApoE-/- animals as compared to healthy age-matched wild-type controls (n=6-
8; p<0.05; data not shown). In contrast, the formation of atherosclerotic lesions did not affect 
aortic expression of H1 and H2 receptor (n=6-8; p=NS; data not shown). Thus, the development 
of atherosclerosis by itself did not interfere with the target of the experimental intervention. 
 
Histamine H1 receptor increases endothelial permeability to LDL 
Histamine is known to increase vascular permeability in acute allergic reactions via the 
H1 receptor (14, 18-21). Enhanced endothelial permeability for LDL is a very important feature of 
atherosclerotic lesion formation (6, 9); however, it is not known whether histamine receptor 
activation is involved. Here we observed that 125I-LDL levels were more than 2-fold higher in the 
aortic wall of 18 week old ApoE-/- animals fed a high cholesterol diet as compared to age- and 
diet-matched ApoE-/-H1R-/- mice (p<0.05; Fig. 2A left panel), while simultaneously measured 125I-
LDL plasma levels did not differ (p=NS; data not shown). These mice exhibited pronounced 
atherosclerotic changes in their descending aortas as assessed by ORO en face staining (Fig. 
2A right panel). The ORO-positive area in aortic cross sections at the level of the aortic valve 
was 24.9±3.2% and 16.5±1.7% of plaque area in ApoE-/- and ApoE-/-H1R-/- mice, respectively 
(p<0.05; Fig. 2B). Similar to mice on a high cholesterol diet, 18 week old ApoE-/- animals fed a 
normal diet showed more than 1.5-fold higher 125I-LDL levels in the aortic wall as compared to 
ApoE-/-H1R-/- mice (p<0.05; Fig. 2C left panel), while while simultaneously measured 125I-LDL 
plasma levels did not differ (p=NS; data not shown). These mice did not exhibit any 
atherosclerotic changes in their descending aortas as assessed by ORO en face staining (Fig. 
2C right panel). 
Hence, the H1 receptor enhances aortic permeability for LDL, which occurs both in the 
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presence and absence of atherosclerotic plaques. These observations indicate that activation of 
the H1 receptor causes a primary alteration of vascular function consisting in an enhanced 
permeability for LDL and in turn on increased intimal accumulation of these lipoproteins and 
increased formation of atherosclerotic lesions. 
 
Histamine H1 receptor does not affect VSMC proliferation  
VSMC proliferation contributes to the progression of atherosclerotic lesions. BrdU 
incorporation over a time period of 7 days was applied to monitor VSMC proliferation during 
atherosclerosis progression in mice fed a high cholesterol diet for 8 weeks. BrdU-positive cells 
occupied 1.4±0.2% of plaque area in ApoE-/- and 1.6±0.2% in ApoE-/-H1R-/- mice (p=NS; data not 
shown). Aortic tissue sections were double-stained with anti-smooth muscle alpha-actin to 
specifically investigate the proliferation of VSMC. The number of double positive cells 
normalized to plaque area was 6.5x10-5±1.1x10-5 cells/µm2 in ApoE-/- and 5.0x10-5±0.7x10-5 
cells/µm2 in ApoE-/-H1R-/- mice (p=NS; Fig. 3A). In line with this, the total area occupied by 
smooth muscle alpha-actin positive cells did not differ in the two groups of animals (p=NS; Fig. 
3B and C). 
These observations indicate that the H1 receptor does not affect VSMC proliferation 
during the formation of atherosclerotic lesions. Both VSMC proliferation and VSMC positive 
plaque area were similar, suggesting that the H1 receptor does not affect VSMC migration 
either. Therefore, the H1 receptor does not promote the formation of atherosclerotic lesions via 
proliferation or migration of VSMC. Histamine was observed to stimulate proliferation of cultured 
VSMC (22); however, these experiments were performed in vitro and do not reflect the complex 
events occurring during plaque formation in vivo. Although VSMC do not contribute to the effect 
of the H1 receptor on plaque formation via proliferation or migration, they may still be involved in 
lesion progression via their metabolic functions. 
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Histamine H1 receptor on vascular, but not on bone marrow derived cells promotes the 
formation of atherosclerotic lesions 
Vascular inflammation is an important event in the formation of atherosclerotic plaques. 
To determine whether the effect of the H1 receptor on lesion formation is mediated by vascular 
or by cells of the hematopoetic system, bone marrow transplantation experiments were 
performed. No difference in plaque formation was observed when reconstitution of ApoE-/- 
recipient mice with ApoE-/- bone marrow (8.0±1.0% aortic plaque area) was compared to that of 
ApoE-/- recipients with ApoE-/-H1R-/- bone marrow (6.4±0.6%; p=NS; Fig. 4). Similarly, plaque 
formation did not differ when ApoE-/-H1R-/- recipient mice were reconstituted with ApoE-/- bone 
marrow (3.3±1.1% aortic plaque area) or with ApoE-/-H1R-/- bone marrow (2.6±0.3%; p=NS; Fig. 
4). In contrast, ApoE-/- recipients exhibited significantly more atherosclerosis as compared to 
ApoE-/-H1R-/- recipients irrespective of whether the mice were reconstituted with ApoE-/- or ApoE-
/-H1R-/- bone marrow (p<0.01 for ApoE-/- recipients vs ApoE-/-H1R-/- recipients with either type of 
bone marrow for reconstitution; Fig 4). 
These data indicate that the H1 receptor expressed on vascular cells rather than on bone 
marrow derived cells promotes the formation of atherosclerotic lesions. The data are in line with 
the observation that the H1 receptor enhances vascular permeability for LDL, since the latter is 
primarily regulated by vascular cells. This notion supports the concept that the increased 
vascular permeability is the driving force for plaque formation through the H1 receptor. Thus, 
histamine promotes plaque formation via the H1 receptor on vascular cells only, although bone 
marrow derived cells still participate in the formation of atherosclerotic lesions and may even 
release histamine under these conditions. Indeed, a reduced neointimal thickening after acute 
vascular injury was demonstrated in mice lacking L-histidine decarboxylase, the rate-limiting 
enzyme for histamine synthesis, and bone marrow derived cells expressing the enzyme 
enhanced neointima formation as compared to cells lacking it. These data indicate that bone 
marrow derived cells are a source of histamine in vivo suggesting that they may release 
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histamine during the formation of atherosclerotic lesions as well. In this case, however, the cells 
would contribute to plaque formation by releasing histamine, but not by responding to it. 
 
Increased aortic and systemic inflammation in the presence of the H1 receptor 
In ApoE-/- mice fed a high cholesterol diet for 12 weeks, immunohistochemistry revealed 
more CD68+ cells in plaques compared to ApoE-/-H1R-/- mice, indicating that the lesions 
contained a higher number of macrophages in the presence of the H1 receptor (p<0.01; Fig. 
5A). A similar pattern was observed with CD3+ T lymphocytes (p<0.01; Fig. 5A) as well as with 
CD4+ T helper cells (p<0.05; Fig. 5A), while the number of CD8+ cytotoxic T cells did not differ 
(p=NS; Fig. 5A). Expression of the chemokine CCL5 (RANTES) was higher in plaques of ApoE-/- 
compared to ApoE-/- H1R-/- mice both at the mRNA and the protein level (p<0.01; Fig. 5B). 
The higher number of macrophages and T lymphocytes in atherosclerotic lesions of mice 
expressing the H1 receptor indicates that inflammation of plaques is more active in the presence 
of the receptor. The enhanced levels of the potent chemokine CCL5 may well account for the 
higher number of leukocytes in these plaques. These data are in line with the concept that the 
increased vascular permeability for LDL is the driving force for plaque formation through the H1 
receptor. When LDL accumulate in the vessel wall, they become oxidized and thereby highly 
chemotactic for leukocytes (9, 23-25); in addition, they induce the production of CCL5 (26, 27), 
which further increases the chemotactic activity in the forming plaques. As leukocytes can 
release histamine, at this stage a positive feedback loop may be induced resulting in the further 
recruitment of inflammatory cells. 
 Similar to the higher number of lymphocytes in plaques of ApoE-/- as opposed to ApoE-/- 
H1R-/- mice, the blood lymphocyte count was 2.86x103±0.27x103 cells/µl in ApoE-/- mice and 
1.71x103±0.28x103 cells/µl in ApoE-/-H1R-/- animals (p<0.01; Fig. 5C). In contrast, no difference 
in the number of blood monocytes, neutrophils, basophils, and eosinophils was observed (p=NS; 
Fig. 5B). The spleen of ApoE-/- animals was 40% larger than that of ApoE-/-H1R-/- mice (p<0.05; 
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Fig. 5D); splenic morphology and cellularity were similar (p=NS; data not shown). Size, 
morphology, and cellularity of inguinal, axillary, and brachial lymph nodes did not differ (p=NS; 
data not shown). 
These differences in blood lymphocyte number and spleen weight between ApoE-/- and 
ApoE-/-H1R-/- mice indicate that there is more systemic inflammation in the presence of the H1-
receptor and reflect the difference in plaque burden between these groups of mice. The animals 
had a similar number of blood lymphocytes and a similar spleen weight prior to initiation of the 
high-cholesterol diet (p=NS; data not shown), underscoring that these differences indeed occur 
secondary to the development of atherosclerosis. 
 
Summary and Conclusions 
This study demonstrates by pharmacological and genetic intervention that histamine 
enhances the development of atherosclerosis via the H1, but not the H2 receptor. The H1 
receptor promotes the formation of atherosclerotic lesions when it is expressed on vascular 
cells, while its presence on bone marrow derived cells is irrelevant for plaque formation. The 
effect of the H1 receptor occurs through an increased vascular permeability leading to LDL 
accumulation and secondary vascular inflammation. These data open interesting perspectives 
for the prevention and treatment of atherosclerosis. 
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Materials and Methods 
 
Animal experiments 
Animals were kept in individually ventilated cages with free access to food and water, 
and maintained at 24°C with 12 hours light/dark cycle. All animal experiments were approved by 
the appropriate authorities.  
 
Pharmacological approach 
6-week old ApoE-/- male mice were treated for 12 weeks with high cholesterol diet (HCD, 
Clinton-Cybulski diet, 1.25% cholesterol, Research Diets #D12108). In parallel, the histamine H1 
receptor blocker mepyramine (10 mg/kg/day, Sigma) or the H2R blocker ranitidine (100 
mg/kg/day, Sigma) was administrated in drinking water. 
 
Genetic approach 
Histamine H1 receptor and H2 receptor knockout mice were kindly provided by Prof. T. 
Watanabe (Graduate School of Medicine, Kyoto University, Yoshida-Konoe machi, Sakyo-ku, 
Kyoto, Japan). These animals were crossed with ApoE-/- mice to generate ApoE-/-H1R-/- and 
ApoE-/-H2R-/- double knockout mice. 6 week old double knockout male mice and ApoE-/- controls 
were treated with a HCD for 12 weeks. 
 
Plasma cholesterol and triglycerides 
Plasma cholesterol was determined using Infinity™ Cholesterol (Thermo Electron 
Corporation Standard #TR13421) and MC Cal (Abbott #1E65-02); plasma triglycerides were 
determined using Infinity™ Triglycerides (Thermo Electron Corporation Standard #TR22421) 
and MC Cal (Abbott #1E65-02). The distribution of lipids within the plasma lipoprotein fractions 
was assessed by fast-performance liquid chromatography (FPLC) gel filtration using a Superose 
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6 HR 10/30 column (Pharmacia). 
 
Quantification of atherosclerosis 
Animals were sacrificed by cervical dislocation. Blood was collected via a right ventricular 
puncture into a syringe flushed with heparin (Braun #46613). Aortas were harvested, fixed with 
4% paraformaldehyde (PFA, Sigma), and stained with Oil red-O (ORO; Sigma #O9755). 
AnalysisFIVE was used for quantification of ORO-positive area. 
 
Immunohistochemistry 
Specimens were frozen at -80°C in O.C.T. compound (Tissue-Tek #62550-01), cut into 8 
µm thick slices, fixed with 4% PFA, and stained with either anti-mouse CD3 (Serotec), CD8 
(Santa Cruz), and CD68 (BD) antibodies, followed by incubation with alkaline phosphatase–
conjugated secondary antibody (Jackson ImmunoResearch). Percentages of stained area were 
quantified with Analysis-FIVE program.  
 
RNA expression 
Total RNA was isolated using RNeasy Mini Kit (Qiagen #74105). cDNA was generated 
using Ready-To-Go You-Prime First-Strand Beads (Amersham Bioscience #27-9264-01) and 
first-strand cDNA primer pd(N)6. Quantitative real-time PCR (qRT PCR) was performed using 
SybrGreen Jump start kit (Sigma #S-4438). Primers were designed to detect mouse chemokine 
(C-C motif) ligand 5 (CCL5), histamine H1 receptor, H2 receptor, and histidine decarboxylase. 
Data were normalized for murine ribosomal S12 and analyzed by the comparative ∆Ct method. 
 
Antibody array 
Mouse Atherosclerosis Antibody Array (Tebu-Bio #126AAM-ATH-1L) was performed 
according to the manufacturer’s instructions. 
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Permeability assay 
In vivo permeability assay was performed as described (28). Animals were anesthetized 
with 80 mg/kg intraperitoneal pentobarbital. Permeability of aorta to LDL was analyzed by using 
human 125I-LDL. 100 µl of buffer containing 5x107 cpm 125 I-LDL and 1% evans blue dye (EBD) 
was injected retroorbitally 30 minute before aortas were harvested. Radioactivity in ice cold 
PBS-washed aortas was normalized to blood radioactivity and aorta weight. All measurements 
were done in triplicate. 
 
FACS 
Splenocytes were isolated using a 70 µm nylon mesh and stained with fluorescently 
labelled anti-mouse CD3 (clone 17A2), CD4 (clone RM4-5), CD8 (clone H35-17.2), CD19 (clone 
1D3), and CD44 (clone IM7) antibodies (all from Pharmingen) for 30 minutes at 4°C. Data were 
collect using DIVAII (BD), and FACS analysis was performed using FlowJo software. 
 
BrdU incorporation 
VSMC proliferation in vivo was determined by 5’-bromo-2’-deoxyuridine (BrdU) 
incorporation. Osmotic pumps (Alzet #1007D) containing BrdU (Serva, infusion rate 13 
mg/kg/day) were implanted under anaesthesia between the shoulder blades. Incorporation of 
BrdU was monitored for 7 days after pump implantation in the region of the aortic root (BD 
Pharmingen #550803). Slides were co-stained using anti-smooth muscle alpha actin antibody 
conjugated with alkaline phosphatase (Sigma #A5691). 
 
Bone marrow transplantation 
BM cells were isolated by flushing femur and tibia bones with ice cold PBS. ApoE-/- and 
ApoE-/-H1R-/- recipient mice were lethally irradiated with 1’100 rads (split dose, within 1 hour) and 
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underwent intravenous rescue injection with 21 x 106 BM cells. After 3 weeks of reconstitution 
time, mice were put on a high cholesterol diet for 12 weeks. 
 
Statistical analysis 
Results are expressed as mean ± standard error of the mean (SEM). Unpaired Student’s 
t-test was applied for comparison of two groups, ANOVA for three or more groups. For each 
experiment, p<0.05 was considered as statistically significant. 
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Legends to Figures and Tables 
 
Figure 1: Histamine H1, but not H2 receptor promotes atherosclerosis  
A) ApoE-/- mice treated with mepyramine (10 mg/kg/day; n=7; p<0.05), but not ranitidine (100 
mg/kg/day; n=8; p=NS) show decreased atherosclerotic plaque formation as compared to mice 
treated with placebo (control; n=12) after 12 weeks of high cholesterol diet.  
B) Representative images (ORO staining) of descending aortas from ApoE-/- mice treated with 
mepyramine, ranitidine, or placebo (control).  
C) ApoE-/-H1R-/- (n=9; p<0.01), but not ApoE-/-H2R-/- mice (n=6; p=NS) show decreased 
atherosclerotic plaque formation as compared to ApoE-/- controls (n=13) after 12 weeks of high 
cholesterol diet.  
D) Representative images (ORO staining) of descending aorta from ApoE-/-H1R-/- and ApoE-/-
H2R-/- mice and ApoE-/- controls.  
 
Figure 2: Histamine H1 receptor enhances vascular permeability to LDL  
A) LDL accumulation is reduced in 18 week old ApoE-/-H1R-/- mice as compared to ApoE-/- 
controls after 12 weeks of high-cholesterol diet (n=5; p<0.05). 125I-LDL in the aortic wall was 
normalized to blood radioactivity and aortic weight. 
B) Representative images (ORO staining) of plaques from ApoE-/-H1R-/- and ApoE-/- animals. 
ApoE-/-H1R-/- animals exhibit less lipid accumulation compared to ApoE-/- controls as determined 
by quantification of ORO-positive area (n=7; p<0.05). 
C) LDL accumulation is reduced in 18 week old ApoE-/-H1R-/- mice as compared to ApoE-/- 
controls after 12 weeks of normal diet (n=6-7; p<0.05). 125I-LDL in the aortic wall was normalized 
to blood radioactivity and aortic weight. 
 
Figure 3: Histamine H1 receptor does not affect vascular smooth muscle cell proliferation 
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A) No difference in the number of smooth muscle alpha-actin (SMa) – BrdU double positive cells 
was observed in atherosclerotic plaques of ApoE-/-H1R-/- mice as compared to ApoE-/- controls 
after 8 weeks of high-cholesterol diet (n=7; p=NS).  
B) No difference in the SMa positive area was observed in atherosclerotic plaques of ApoE-/-
H1R-/- mice as compared to ApoE-/- controls (n=7; p=NS). 
C) Immunohistochemical staining for SMa in atherosclerotic plaques of ApoE-/-H1R-/- mice and  
ApoE-/- controls. 
 
Figure 4: Histamine H1 receptor on vascular cells, but not bone marrow-derived cells 
enhances the development of atherosclerosis 
Percentage plaque area (A) and representative en-face ORO stained aortic sections (B) after 
indicated transplantation protocol. See text for details. **p<0.01, n=4-6. 
 
Figure 5: Enhanced inflammation in the presence of the H1 receptor 
A) The number of CD68 (n=9-10; p<0.005), CD3 (n=12-13; p<0.05), and CD4 positive cells 
(n=10; p<0.05) was higher in atherosclerotic plaques of ApoE-/- compared to ApoE-/-H1R-/- mice 
after 12 weeks of high-cholesterol diet. The number of CD8-positive cells was similar (n=12, 
p=NS). Three sections of every specimen at a distance of 100 µm each were stained. 
B) CCL5 expression at the mRNA and protein level was higher in aorta of ApoE-/- compared to 
ApoE-/-H1R-/- mice after 12 weeks of high-cholesterol diet (n=10; p<0.05). 
C) The number of circulating lymphocytes was higher in ApoE-/- compared to ApoE-/-H1R-/- mice 
after 12 weeks of high-cholesterol diet (left panel; n=8-9; p<0.01); in contrast, no difference in 
the number of monocytes, neutrophils, eosinophils or basophils was observed (table).  
D) Spleen weight was higher in ApoE-/- compared to ApoE-/-H1R-/- mice after 12 weeks of high-
cholesterol diet (left panel; n=10; p<0.05). 
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Table 1: Plasma triglyceride and plasma cholesterol level, daily food intake, and weight of 
ApoE-/- and ApoE-/-H1R-/- mice after 12 weeks of HCD. 
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ApoE-/- 0.61 ± 0.14 17.23 ± 7.21 2.75 ± 0.32 28.38 ± 2.38
ApoE-/-H1R-/- 0.84 ± 0.31 16.24 ± 4.42 2.73 ± 0.40 31.22 ± 3.71*
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Abstract 
 
Atherosclerosis is an inflammatory disease characterized by accumulation 
of leukocytes in the arterial intima. Members of the selectin family of adhesion 
molecules are important mediators of leukocyte extravasation. It is not known, 
however, whether L-selectin (L-sel) is involved in the pathogenesis of 
atherosclerosis. 
To address this issue, we crossed L-sel-/- animals with mice lacking 
Apolipoprotein E (ApoE-/-). We analyzed double-knockout ApoE / L-sel (ApoE-/- L-
sel-/-) mice and the corresponding ApoE-/- controls both without and with a high 
cholesterol diet (HCD). 
After 6 weeks of HCD ApoE-/- L-sel-/- mice developed on average 2.46% ± 
0.54% aortic lesions which is two fold higher than ApoE-/- controls (1.13% ± 
0.19%). This effect was even more pronounced in 6 month old ApoE-/- L-sel-/- 
animals fed a normal diet. In contrast, after 12 weeks of HCD, there was no 
difference in atheroma formation between the two groups of animals. Leukocyte 
rolling in atherosclerotic aorta was similar in ApoE-/- and ApoE-/- L-sel-/- animals. In 
line with this, atherosclerotic plaques did not exhibit any alterations in cellular 
composition upon L-sel deletion after 6 and 12 weeks of HCD. Mice lacking L-sel 
exhibited reduced size and cellularity of peripheral lymph nodes, increased size 
of spleen, and increased number of blood lymphocytes after 6 and 12 weeks of 
HCD.  
These results indicate that L-sel is a negative regulator of early, but not 
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advanced atherosclerosis. This effect is neither associated with leukocyte 
capture nor abnormal leukocyte distribution. 
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Introduction 
 
 Endothelial activation followed by leukocyte accumulation is the key event 
in early atherosclerosis [1]. The selectin family of adhesion molecules mediates 
initial rolling and tethering of inflammatory cells along activated endothelium [2-6]. 
It consists of three closely homologous glycoproteins; E-selectin (E-sel), P-
selectin (P-sel), and L-selectin (L-sel) that all bind glycoproteins and glycolipids 
bearing sialyl Lewis X (sLeX) in a calcium-dependent manner [7, 8]. E-sel is 
expressed on endothelial cells, whereas P-sel on both EC and platelets on which 
they are expressed on the cell surface following stimulation. L-sel, on the other 
hand, is expressed constitutively on the majority of leukocytes [6]. It exhibits 
adhesive as well as signaling functions [9, 10] and is particularly important for 
lymphocyte homing to secondary lymphoid organs [5, 11]. Indeed, animals 
lacking L-sel display altered size of secondary lymphoid tissues, increased 
number of blood lymphocytes, and abnormal immunoglobulin profile [11-13]. 
Moreover, L-sel deficient mice show reduced in vivo leukocyte rolling along 
cytokine-stimulated endothelium. This phenomenon is particularly well 
documented in blood vessels belonging to the microcirculation and depend 
primarily on a lack of L-sel-mediated interactions between leukocytes that 
regulate enhanced capture of cells from the free flow [14, 15]. Indeed, functional 
L-sel ligand activity has not been identified on inflamed EC [16].  
Since selectins are known to regulate leukocyte recruitment in 
inflammation, they are interesting candidates to study in the context of 
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atherogenesis. Indeed, mice deficient in E- and P-sel display attenuated 
development of atherosclerosis [2, 17]. Interestingly, it was reported that 
lymphocyte recruitment into the aortic wall during atherosclerosis development is 
partially L-sel dependent [18]. However, there are no in vivo reports addressing 
the importance of L-sel in atherosclerosis development in vivo. Here, we crossed 
L-sel-/- mice with Apolipoprotein E-deficient mice (ApoE-/-) to investigate the 
relevance of L-sel on both early and advanced stage of atherosclerosis. 
Interestingly, we showed that atherosclerotic mice deficient in L-sel have an 
increased early atherosclerosis. These data demonstrate the complexity of the 
roles for the immune system in atherogenesis. 
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Results 
 
Deletion of L-selectin increases early, but not advanced atherosclerosis. 
Development of atherosclerosis was monitored in descending aortas using 
Oil red-O (ORO) staining. Percentage of aorta occupied by atherosclerotic 
plaques was two fold higher in 12 week old ApoE-/- L-sel-/- animals fed a HCD for 
6 weeks when compared to age and diet-matched ApoE-/- controls (2.46% ± 
0.54% versus 1.13% ± 0.19% respectively; P<0.05; Fig. 1A). Effect of L-sel 
deletion was even more pronounced in 6 month old animals fed a normal chow 
diet. These animals had on average 10.45 ± 2.58% of descending aorta stained 
by ORO, whereas controls only 1.87 ± 0.37% (P<0.05; Fig. 1B). In contrast 18 
week old ApoE-/- L-sel-/- animals fed a HCD for a time period of 12 weeks 
exhibited on average similar atherosclerotic burden (11.80 ± 1.86%) as ApoE-/- 
animals (13.89 ± 2.06%; P=ns; Fig. 1C). There was no difference between 
control mice and double knockouts in plasma cholesterol level in any of the 
groups (P=ns; Table S1). 
 
Deletion of L-selectin does not influence leukocyte capture and rolling in 
atherosclerosis. 
Leukocyte capture and rolling were assessed using intravital microscopy during 
30 seconds. Total number of cells rolling along the aortic endothelium was similar 
in ApoE-/- L-sel-/- and ApoE-/- animals (P=ns; Fig. 2A) and proportional to total 
leukocyte capture (R2=0.8; Fig. 2B). There was no difference between ApoE-/- 
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and ApoE-/- L-sel-/- animals in primary leukocyte capture (5.4 ± 1.3 cells versus 
5.5 ± 1.3 cells respectively; P=ns; Fig. 2C) and a tendency towards reduced 
secondary leukocyte capture (1.28 ± 0.92 cells versus 0.17 ± 0.14 cells 
respectively; P=ns; Fig. 2D). 
 
Deletion of L-selectin does not influence leukocyte accumulation into 
atherosclerotic plaques. 
In order to monitor composition of atheroma upon L-sel deletion we 
performed immunostainings of the atherosclerotic plaques in the aortic root area. 
Macrophages were visualized with anti-CD68 antibody, lymphocytes with anti-
CD3 antibody and T-helper cells and T-cytotoxic cells with anti-CD4 and anti-
CD8 antibodies respectively. L-sel deletion did not result in altered CD68 positive 
area in either early (71.10% ± 1.36% versus 74.44% ± 2.90%; P=ns; Fig. 3A) or 
advanced atherosclerosis (48.20% ± 4.13% versus 39.62% ± 1.99%; P=ns; Fig. 
3A). There was no difference between ApoE-/- and ApoE-/- L-sel-/- mice in average 
number of CD3 (P=ns; Fig. 3B), CD4 (P=ns; Fig. 3C), and CD8 positive cells 
when related to a plaque area (P=ns; Fig. 3D) after 6 and 12 weeks of HCD. 
Increased duration of HCD resulted in decreased macrophage/plaque area ratio, 
which did not depend on the genotype of animals (P<0.05; Fig. 3A). There was 
no diet-dependent difference in accumulation of T-cells (P=ns). The expression 
of cytokines was similar in aortas of ApoE-/- L-sel-/- mice compared to ApoE-/-
controls after both 6 and 12 weeks of HCD (P=ns; Table 1). In contrast, 
irrespectively of the genotype, animals after 12 weeks of HCD exhibited 
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consistently enhanced cytokine production compared to animals after 6 weeks of 
HCD (P<0.05; Table 1). 
 
Increased number of blood lymphocytes upon L-selectin deletion. 
We observed 1.4 fold and 1.6 fold increased number of blood lymphocytes 
in ApoE-/- L-sel-/- animals compared to ApoE-/- controls after 6 and 12 weeks of 
HCD respectively (P<0.05; Fig. 4A). Indeed total number of CD8+ cells and 
CD19+ cells was on average 20% to 40% increased upon L-sel deletion 
irrespectively of the time of HCD (P<0.05; Fig. 4B and C). After 6 weeks of HCD 
there was tendency towards increased number of CD4+ cells (P=0.24), which 
became significant after 12 weeks of HCD (P<0.05; Fig. 4D). Increased number 
of blood lymphocytes in ApoE-/- L-sel-/- mice was associated with increased 
number of naive T helper/CD4+CD44- cells (P<0.05; Fig. 4E) rather than 
activated T helper/CD4+CD44+ cells (P=ns after 6 weeks of HCD, P<0.05 after 12 
weeks of HCD; Fig. 4F). We did not detect any significant difference in blood 
composition of mice after 6 and 12 weeks of HCD in any of the genotypes. 
We observed significant reduction in the size (P<0.05; Fig. S1 A) and 
cellularity of peripheral lymph nodes (P<0.05; Fig. S1 B). In contrast, size of the 
spleen was on average 30% increased upon L-sel deletion in both time-points 
(P<0.05; Fig; S2 A), this was not associated with altered cellularity of the organ 
(P=ns; Fig. S2 A) or altered cytokine production (P=ns, data not shown). 
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Materials and Methods 
 
Mice 
L-sel knockout mice backcrossed for 9 generations to C57BL/6 
background were a kind gift from Dr Lubor Borsig (Physiology Institute, Zurich 
University, Switzerland). L-sel knockouts were cross-bred with ApoE-/- mice to 
generate ApoE-/- L-sel-/- and littermate ApoE-/- controls. 6 week old males were 
fed for 6 or 12 weeks a HCD (Clinton-Cybulski diet, 1.25% cholesterol, Research 
Diets #D12108). In addition 6 month old ApoE-/- L-sel-/- animals and controls fed a 
normal chow diet were analyzed. All animal experiments were approved by the 
appropriate authorities.  
 
Quantification of atherosclerosis development 
Under anesthesia, blood was collected through right ventricular puncture. 
Mice were then perfused with ice-cold saline. Aortas were harvested for RNA 
isolation, en face, and histological analysis. Thoracic/abdominal part of aortas 
were fixed overnight with 4% paraformaldehyde (PFA), washed 3 times with ice-
cold PBS, and stained for 3 hours with Oil red-O (Sigma #O9755). Quantification 
of aortic plaque area was performed using AnalysisFIVE software.  
 
Plasma triglyceride and cholesterol level 
Plasma cholesterol level was determined using Infinity™ Cholesterol 
(Thermo Electron Corporation Standard #TR13421) and MC Cal (Abbott #1E65-
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02), plasma triglycerides using Infinity™ Triglycerides (Thermo Electron 
Corporation Standard #TR22421) and MC Cal (Abbott #1E65-02). The 
distribution of lipids within the plasma lipoprotein fractions was assessed by fast-
performance liquid chromatography (FPLC) gel filtration using a Superose 6 HR 
10/30 column (Pharmacia). 
 
Immunohistochemistry 
Tissue was harvested, mounted in O.C.T. compound (Tissue-Tek #62550-
01) and frozen at -20°C. Three to five 8 µm-thick slices were fixed with 4% PFA 
and stained with anti-mouse CD3, CD4 CD8, or CD68 antibodies (Serotec), 
followed by incubation with alkaline phosphatase–conjugated secondary antibody 
(Jackson ImmunoResearch). Percentages of stained area were quantified with 
AnalySIS-FIVE program.  
 
Intravital microscopy 
Mice were anesthetized with isofluran. The aorta was prepared as 
described previously [19]. Briefly, the abdomen was opened by a midline incision 
and the intestines were retracted. The peritoneum was then dissected to expose 
the abdominal aorta. The exposed tissue was superfused with a thermostated 
(37°C) bicarbonate-buffered saline solution. Microscopic observations were 
made using an intravital microscope (Leitz Biomed) with a water immersion 
objective (Leitz SW 25×). Epi-illumination fluorescence microscopy (Leitz Ploem-
o-pac, filter block M2 illuminated by a cooled infrared filtered lamp (Osram HBO 
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200W/4)) was started 2 minutes after labeling of circulating leukocytes with an 
intravenous injection of rhodamine 6G (0.3 mg/ml, 0.67 mg/kg). Images were 
televised and recorded on videotape using a VNC-703 video camera. Leukocyte 
rolling flux was determined as the average number of leukocytes rolling within a 
10000 µm2 area during 30 seconds within a total observation time of at least 180 
seconds. 
 
FACS 
Blood cells were stained with fluorescently labeled anti-mouse CD4 (PE-
conjugated, clone RM4-5), CD8 (PE-Cy7-conjugated, clone H35-17.2), CD19 
(PE-Cy7-conjugated, clone 1D3), and CD44 (APC-conjugated, clone IM7) 
antibodies (Pharmingen) for 30 minutes at 4°C. Erythrocytes were lyzed following 
staining using commercially available lysis buffer (BD #555899). Data were 
collected using DIVAII (BD), and FACS analysis was performed using FlowJo 
software. 
 
Statistical analysis 
The results were expressed as mean ± S.E.M. Comparison of means was 
carried out by Student’s t-test or ANOVA in case of multiple comparisons. For 
each experiment, P<0.05 was accepted as statistically significant. 
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Discussion 
 
 Accumulation of leukocytes into the arterial wall is an important pathogenic 
event in atherosclerotic plaque development. It is well documented that the 
selectin family of adhesion molecules mediates the initial attachment of 
leukocytes to activated endothelium, representing the first step of leukocyte 
emigration into sites of inflammation [2, 6]. Recently, it was postulated that 
lymphocyte recruitment during atherosclerosis development is partially L-sel 
dependent [18]. Thus, we hypothesized that deletion of L-sel might affect 
atherogenesis due to impaired leukocyte rolling and capture. To test this 
hypothesis we generated ApoE-/- L-sel-/- mice and compared them to ApoE-/- 
controls.  
 Despite the partial L-sel dependence of lymphocyte recruitment in 
atherogenesis, we found that L-sel does not promote atherosclerotic lesion 
formation in 6 month old ApoE-/- mice fed a normal chow diet as well as after a 6 
or 12 week HCD. This observation suggests that under conditions of L-sel 
deletion, the presence of other members of the selectin family is sufficient to 
maintain leukocyte-endothelium interactions. It is consistent with some previous 
reports on overlapping functions of the selectins [17, 20, 21]. Indeed, any of the 
selectins can support some leukocyte rolling, and only the deletion of all three 
family members abolishes leukocyte recruitment [20, 21]. Combined, but not 
single deletion of E-sel and P-sel results in reduced atherosclerosis development 
[17]. In line with this, we did not observed any difference between ApoE-/- L-sel-/- 
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and ApoE-/- mice with regard to leukocyte capture or rolling in atherosclerotic 
aorta.  
 The effect of L-sel deletion on atherosclerotic lesion formation seems to 
contradict other studies emphasizing the importance of L-sel in the initial stages 
of leukocyte extravasation [11, 14, 22]. However, most of these studies were 
conducted in microvessels, whereas atherosclerosis is a disease of large 
arteries. The wall of microvessels is known to exhibit different properties than that 
of large arteries, including the expression of distinct L-sel ligands [23]. MadCAM-
1, the only well characterized in vivo ligand of L-sel is expressed in ECs from the 
microcirculation, but not in larger blood vessels [24]. Thus, the effect of L-sel on 
leukocyte rolling in venules or arterioles may not be relevant for atherosclerosis 
development. In line with this, the presence of a functional L-sel ligand on 
inflamed endothelium remains controversial [16, 25], and some studies 
demonstrated that primary capture resulting from leukocyte-endothelium 
interaction is not affected by L-sel [14]. Thus, we monitored both primary capture 
as well as secondary capture defined as the interaction of L-sel with selectin 
glycoprotein ligand-1 (PSGL-1) on the surface of other leukocytes. We did not, 
however, observe any differences in primary leukocyte capture and only a trend 
towards decreased secondary capture upon L-sel deletion. This observation 
indicates either that L-sel is not essential for secondary leukocyte capture or 
secondary capture does not affect leukocyte extravasation during atherosclerosis 
development. 
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 In the study postulating that leukocyte accumulation into the arterial wall 
during atherosclerosis development is partially L-sel dependent, accumulation of 
fluorescently labeled L-sel deficient lymphocytes to atherosclerotic aortas was 
monitored 24 and 72 hours after adaptive transfer to ApoE-/- recipients. Upon 
these conditions deletion of L-sel resulted in a 50-57% reduction in leukocyte 
rolling. In contrast, we applied intravital microscopy to study leukocyte rolling 
along the aorta of ApoE-/- and ApoE-/- L-sel-/- mice during atherosclerosis 
development in vivo. Adaptively transferred cells do not function in their natural 
environment and may exhibit altered properties due to the isolation procedure; in 
contrast, we investigated the intrinsic properties of native leukocytes during 
atherogenesis. Hence, the discrepancy between these two observations may 
result from the different experimental setting. 
 Plaques of ApoE-/- L-sel-/- mice exhibited similar numbers of macrophages 
and T cells as compared to ApoE-/- controls. Thus, the cellular composition of 
atherosclerotic plaques was not affected by L-sel deletion irrespective of the 
presence or the duration of HCD. This supports the interpretation that the 
absence of L-sel is not sufficient to influence the initial stages of leukocyte 
transmigration during atherosclerosis development. In line with this, we did not 
detect any difference in cytokine production in atherosclerotic vessel walls, 
indicating a similar extent of the local inflammatory state in ApoE-/- and ApoE-/- L-
sel-/- animals. In contrast, animals treated for 12 weeks with a HCD exhibited 
enhanced aortic cytokine levels as compared to animals treated 6 weeks with a 
HCD, consistent with a more advanced stage of atherosclerosis in these mice. 
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 L-sel had an atheroprotective effect in animals without a HCD and in those 
fed a HCD for 6 weeks, but not for 12 weeks. This indicates a role for L-sel in the 
early, but not the advanced stages of atherosclerosis. The increased 
atherosclerotic burden in the animals lacking L-sel may result from an altered 
local inflammation or abnormal systemic leukocyte distribution. 
 The inflammatory state of atherosclerotic plaques is an important 
determinant of atherosclerosis development [1]. Indeed, it was demonstrated that 
deletion of cytokines and adhesion molecules expressed specifically by the 
vascular wall attenuates atherosclerosis development [17, 26, 27]. We did not, 
however, observe any difference between ApoE-/- L-sel-/- mice and controls in 
aortic levels of pro- and anti-inflammatory molecules, suggesting a similar 
inflammatory state within the plaques in these animals. In line with this, there was 
no difference between L-sel deficient mice and controls in cellular composition of 
the atherosclerotic plaques. 
 Atherosclerosis affects not only the wall of blood vessels, but also 
provokes changes at the systemic level [28, 29]. Deletion of L-sel resulted in 
abnormal systemic leukocyte distribution, which could potentially affect 
atherosclerosis development [30]. As expected, both size and cellularity of 
peripheral lymph nodes were decreased in ApoE-/- L-sel-/- mice as compared to 
ApoE-/- controls. This is consistent with observation that migration of naive 
lymphocytes into peripheral lymph nodes is practically eliminated upon L-sel 
deletion [11, 13]. The spleen cannot fully compensate for the cessation of 
leukocyte homing to peripheral lymph nodes [11], thus, L-sel deficiency result in 
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increased numbers of blood lymphocytes. Although changes in blood leukocyte 
numbers were demonstrated to correlate with progression of atherosclerosis [31], 
leukocyte capture and cellular plaque composition were not affected by the 
absence of L-sel. Moreover, leukocyte distribution in ApoE-/- L-sel-/- mice was 
comparable in animals fed 6 and 12 weeks a HCD. Hence, they do not explain 
the differences in atherosclerotic plaque formation between these animals.  
 To summarize, we demonstrated for the first time that L-sel attenuates 
early stages of atherosclerosis, which is not associated with reduced leukocyte 
rolling or leukocyte accumulation into atherosclerotic plaques. Further studies are 
required to clarify the mechanism of this phenomenon.  
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Legends to Figures and Tables 
 
Figure 1 
Atherosclerosis development in L-sel-/- mice lacking ApoE. Representative 
pictures of aortas stained with Oil-Red-O (ORO). Atherosclerotic lesion area 
expressed as a percentage of total aortic area. Increased atherosclerotic burden 
in A) 12 week old ApoE-/- L-sel-/- animals after 6 weeks of HCD (n=11-15; 
*P<0.05); and B) 6 month old ApoE-/- L-sel-/-  animals fed a normal chow diet as 
compared to ApoE-/- controls (n=5-9; *P<0.05), but not C) 18 week old animals 
after 12 weeks of HCD (n=10-15; P=ns) as compared to ApoE-/- controls. 
 
Figure 2 
L-sel does not affect leukocyte capture and rolling during atherosclerosis. 
A) Leukocyte rolling in atherosclerotic aorta was not affected by the absence of 
L-sel (n=7; P=ns). B) Total capture of leukocytes was proportional to leukocyte 
rolling flux (R=0.8). There was no difference between ApoE-/- and ApoE-/- L-sel-/- 
animals in either C) primary or D) secondary leukocyte capture (n=7; P=ns).  
 
Figure 3 
Similar cellular composition of atherosclerotic plaques in ApoE-/- L-sel-/- 
mice and ApoE-/- controls. Immunostainings were performed to visualize A) 
macrophages/CD68+, B) T-lymphocytes/CD3+, C) T helper cells/CD4+, and D) T-
cytotoxic cells/CD8+ after 6 and 12 weeks of HCD (n=5-13; P=ns). 
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Figure 4  
Altered blood composition in atherosclerotic L-sel-/- animals. Increased 
number of A) total blood lymphocytes (n=5-8; *P<0.05) upon L-sel deletion 
associated with increased number of B) T-cytotoxic cells/CD8+ (n=6-7; **P<0.01, 
#P<0.05). C) B lymphocytes/CD19+ (n=5-7; *P<0.05, #P<0.05), D) total/CD4+, and 
E) naive T-helper cells/CD4+CD44- (n=5-7; *P<0.05, ##P<0.0001) after 6 and 12 
weeks of HCD respectively. F) Number of activated T-cells/CD4+CD44+ remained 
unchanged after 6 weeks of HCD (n=5-7; P=ns) and decreased after 12 weeks of 
HCD (n=5-7; *P<0.05) compared to corresponding controls. 
 
Table 1  
Cytokine mRNA abundance is not affected by an absence of L-sel. 
 
Supplement 
 
Figure S1 
Decreased A) size (n=5-6; **P<0.01, ##P<0.01) and B) cellularity (n=5-6; *P<0.05, 
#P<0.05) of peripheral lymph nodes (LN) in mice lacking L-sel after both 6 and 12 
weeks of HCD. 
 
Figure S2 
A) Increased size of the spleen upon L-sel deletion (n=6; **P<0.01, #P<0.05). B) 
Cellularity of the organ was not affected by L-sel deletion (n=5-6; *P>0.05). 
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Table S1 
Plasma cholesterol and triglyceride levels (n=5-12; P=ns). 
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Table 1
6 weeks 12 weeks
expression level ApoE-/- ApoE-/- L-sel-/- ApoE-/- ApoE-/- L-sel-/-
MCP-1 (x10-2) 2.02 ± 0.58 2.59 ± 0.37 5.22 ± 1.47 5.95 ± 1.20
TNF ( 10-3) 1 40 0 39 1 40 0 15 3 90 1 30 4 2 1 01α x .  ± . . ± . .  ± . .  ± .
INFγ (x10-4) 4.51 ± 1.8 3.88 ± 0.7 18.71 ± 8.00 25.45 ± 10.30
Mip-1 (x10-2) 3.44 ± 0.59 2.84 ± 0.36 5.88 ± 1.88 3.14 ± 0.65
IL-4 (x10-4) 4.43 ± 1.20 3.51 ± 0.4 11.01 ± 3.7 10.11 ± 2.7
IL-6 (x10-3) 1.11 ± 0.22 1.34 ± 0.25 2.32 ± 0.64 2.22 ± 0.59
4IL-10 (x10- ) 2.22 ± 1.00 2.79 ± 0.40 6.51 ± 1.60 4.79 ± 1.3
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Table S1
no  wee s  wee s
mmol/L ApoE-/- ApoE-/-L-sel-/- ApoE-/- ApoE-/-L-sel-/- ApoE-/- ApoE-/-L-sel-/-
cholesterol 9.16 ± 1.19 10.48 ± 0.77 32.88 ± 1.53 30.10 ± 1.95 32.31 ± 2.03 30.78 ± 2.53
triglyceride 1.56 ± 0.13 1.73 ± 0.18 1.25 ± 0.19 1.35 ± 0.23 1.27 ± 0.17 0.94 ± 0.08
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Abstract 
 Oxidized low-density lipoprotein (oxLDL) plays a major role in 
atherogenesis. Although lectin-like oxLDL receptor-1 (LOX-1) is the main oxLDL 
receptor expressed by endothelial cells (ECs), its importance in atherogenesis in 
vivo remains unknown.  
 To address this issue, we generated endothelial-specific LOX-1 transgenic 
mice (LOX-1 TG) using the Tie2 promoter. Indeed, overexpression of LOX-1 in 
ECs, but not in macrophages, resulted in enhanced oxLDL uptake. To investigate 
potential atherogenic effects of LOX-1 in vivo, 6-week-old LOX-1 TG and wild-type 
(WT) mice were fed a high cholesterol diet (HCD) for 30 weeks. In addition, LOX-1 
TG animals were crossbred with apolipoprotein E deficient mice (ApoE-/-) and fed 
HCD for 20 weeks. LOX-1 overexpression resulted in enhanced atherosclerosis, 
which was associated with impaired EC-dependent relaxation to acetylcholine. In 
addition, in both LOX-1 TG and LOX-1 TG/ApoE-/- mice, we observed increased 
aortic expression of adhesion molecules. In line with this, the number of leukocytes 
in atherosclerotic plaques of animals overexpressing LOX-1 was increased 
compared to controls. 
 Thus, endothelial-specific overexpression of LOX-1 leads to increased 
atherosclerotic burden due to enhanced endothelial cholesterol uptake, increased 
expression of adhesion molecules, and, as a result, increased leukocyte 
extravasation. Therefore, LOX-1 may be a promising therapeutic target for 
atherosclerosis. 
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Introduction 
 Atherosclerosis is a chronic inflammatory disease initiated by endothelial 
activation and induced, among the others, by the oxLDL uptake [1, 2]. This process 
leads eventually to adhesion and transmigration of leukocytes into arterial intima 
and promotes atherosclerotic plaque formation [1, 3]. OxLDL can be scavenged by 
both, ECs and macrophages [4, 5]. While macrophages internalize oxLDL by 
receptors such as scavenger receptor A (SR-A), SR-BI, and CD36 [6-8], in ECs, 
the oxLDL uptake depends primarily on the LOX-1 [9-11].  
 LOX-1 is a type II membrane glycoprotein with a molecular weight of 50 
kDa. It has a C-terminal extracellular C-type lectin-like domain, which is essential 
for binding to oxLDL [12]. In cultured endothelial cells, activation of LOX-1 by 
oxLDL upregulates the expression of several genes involved in endothelial 
dysfunction, such as MCP-1, ICAM-1, and VCAM-1 and reduces NO release [13-
15]. Thus, internalization of oxLDL leads to ECs activation and, eventually, 
atherosclerosis development [13, 16-18]. Indeed, oxLDL-induced endothelial 
dysfunction has been implicated in atherogenesis and LOX-1 expression is 
increased in atherosclerotic plaques [9, 19, 20]. Moreover, it was recently reported 
that deletion of LOX-1 attenuates atherosclerosis in low-density lipoprotein 
receptor knockout mice due to reduced collagen deposition and metalloproteinases 
expression [21]. 
 Although the role of LOX-1 in ECs activation is well described, there are no 
in vivo studies clarifying its relevance in atherosclerosis. Therefore, we generated 
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LOX-1 TG mice to investigate the importance of endothelial oxLDL uptake in 
atherosclerotic plaques development in vivo. 
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Results and Discussion 
 To investigate the role of LOX-1 in atherogenesis, we generated mice with 
endothelial overexpression of LOX-1 driven by the endothelial-specific Tie2 
promoter [22]. Animals overexpressing LOX-1 in ECs (Fig. 1A) carried a different 
copy number of LOX-1 transgene (Fig. 1B). The line 5048.1, which showed the 
highest transgene expression, was selected for further experiments. Real time 
PCR analysis revealed highest LOX-1 expression in the aorta, although low 
expression was also detected in the kidney (Fig. 1C). Aortic LOX-1 overexpression 
was confirmed in LOX-1 TG mice by Western blotting (Fig. 1D). 
Immunohistochemical staining visually confirmed that specific overexpression of 
LOX-1 is confined to ECs (Fig. 1E). To further test specificity of LOX-1 
overexpression, ECs were isolated from murine aortas. The purity of cells was 
confirmed with FACS (Fig. 2A). As expected, in cultured ECs isolated from LOX-1 
TG mice, oxLDL uptake was increased compared to those isolated from WT mice 
(Fig. 2B, and C). Importantly, there was no difference in Dil-oxLDL uptake in 
cultured LOX-1 TG and WT macrophages (data not shown). Thus, although Tie2 
promoter was reported to be active also in macrophages [23, 24], it appears, that 
other scavenger receptors like SR-A, CD36, and SR-BI play a dominant role in 
oxLDL uptake in these cells. These findings underline the specific functional effects 
of endothelial-specific LOX-1 overexpression. 
 To examine the effects of LOX-1 overexpression on atherogenesis, we fed 
LOX-1 TG and WT male mice a HCD for 30 weeks starting at 6 weeks of age. 
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LOX-1 TG mice exhibited increased fatty streak formation in aortic root as 
compared to WT controls (Fig. 3A, and B). Since plasma lipid levels were 
comparable in LOX-1 TG and WT mice (Tab. 1), this difference is likely to be 
related to an increased activity of endothelial LOX-1 receptor.  
 In cultured ECs, LOX-1 activation enhances the expression of chemokines 
and adhesion molecules [14, 15]. These cellular events, together with the 
chemoattractant properties of LOX-1 itself [25], could facilitate accumulation of 
oxLDL as well as macrophage infiltration into the vascular wall leading to 
progression of atherosclerosis. In line with this, aortic vascular cell adhesion 
molecule-1 (VCAM-1) and E-selectin (E-sel) mRNA level was enhanced in the 
LOX-1 TG compared to WT mice (Fig. 4A and B). This was confirmed by 
immunohistochemistry showing increased endothelial expression of VCAM-1 in 
LOX-1 TG mice (Fig. 4C and D). E-sel expression was not detectable with this 
method. Adhesion molecules play an important role in the transmigration of 
leukocytes into atherosclerotic plaques [26]. Indeed, the number of activated 
macrophages (CD68 positive area) was increased in the aorta of LOX-1 TG mice 
compared to controls (Fig. 4E and F).  
 To investigate the effects of LOX-1 overexpression on advanced 
atherosclerosis, LOX-1 TG mice were cross-bred with ApoE-/- on C57BL/6 
background and resulting LOX-1 TG/ApoE-/- and ApoE-/- littermates were fed a 
HCD for 20 weeks starting at 6 weeks of age. As an endothelial dysfunction 
precedes plaque formation [27, 28], we assessed endothelium-dependent 
relaxation in the aortic rings from both groups. Indeed, in LOX-1 TG/ApoE-/- mice, 
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acetylcholine induced endothelium-dependent relaxation was reduced (pEC50 (-
log M): 6.34±0.12); Emax (% of contraction) 6.52±3.05%) compared to those of 
ApoE-/- mice (6.67±0.40, P>0.05; Emax (% of contraction) 22.18±6.68%; P<0.05). In 
contrast, endothelium-independent relaxation to sodium nitroprusside was 
comparable in both groups (data not shown). These data demonstrate profound 
endothelial dysfunction induced by overexpression of LOX-1 during atherosclerosis 
development.  
 Furthermore, atherosclerotic plaque area was increased almost two-fold in 
LOX-1 TG/ApoE-/- as compared to ApoE-/- controls (Fig. 5A and B). To determine 
the effects of endothelial-specific LOX-1 on the expression of adhesion molecules 
in the ApoE-/- background, immunohistochemical staining for VCAM-1 and P-
selectin (P-sel) was performed on cross sections of aortic roots (Fig. 6A and D). 
Analysis revealed increased expression of both VCAM-1 (Fig. 6A and B) and P-sel 
(Fig. 6D and E) in LOX-1 TG/ApoE-/- mice compare to controls. RNA analysis 
confirmed increased VCAM-1, but not P-sel abundance (Fig. 6C). It agrees with 
previous reports demonstrating that expression of P-sel is regulated primarily on 
the posttranscriptional level [29]. In line with these findings, the number of 
macrophages (CD68-positive areas; Fig. 7A and B) and T-cells (CD3-positive 
areas; Fig. 7C and D) was increased in atherosclerotic plaques of LOX-1 TG/ApoE-
/- mice compared to controls. Thus, LOX-1 overexpression in vivo results in 
increased atherosclerotic lesion formation independent of the plasma lipoprotein 
levels. Rather, increased endothelial uptake mediated by the overexpression of a 
functional LOX-1 transgene is involved in that process. Our data correlate well with 
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a recent study in LOX-1 knockout mice, where decreased level of atherosclerosis 
was measured [21]. In other study overexpression of bovine LOX-1 driven by a 
preproendothelin-1 promoter resulted in inflammatory intramyocardial vasculopathy 
[30]. However, a preproendothelin-1 promoter, in contrast to the Tie2 promoter 
used in this study, drives the expression of the LOX-1 transgene predominantly in 
microvessels leading to a vasculatis rather than to atherosclerotic changes. 
Furthermore, species differences in the bovine versus murine LOX-1 gene could 
bias the results. 
 In summary, our data strongly support the thesis that endothelial-specific 
overexpression of LOX-1 leads to endothelial dysfunction and enhanced 
atherosclerotic plaque formation in both C57BL/6 and ApoE-/- mice.  
Indeed, we showed increased in vivo expression of VCAM-1 and E-sel in aortas of 
LOX-1 TG mice as well as an increased expression of VCAM-1 and P-sel in aortas 
of LOX-1 TG/ApoE-/- mice compared to corresponding controls. This was 
associated with impaired EC-specific relaxation to acetylcholine. This finding 
indicates that LOX-1 promotes ECs activation under hyperlipidemic conditions. In 
line with these molecular events, an increased numbers of leukocytes were 
observed in the atherosclerotic lesions of mice overexpressing LOX-1. 
 We believe that the development of strategies aimed at endothelial-specific 
inhibition of LOX-1 may open new therapeutic approaches for the prevention as 
well as for the treatment of atherosclerosis. 
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Materials and Methods 
 
Generation of LOX-1 transgenic mice 
 To obtain transgenic mice specifically overexpressing LOX-1 in EC, a 
murine tyrosine kinase receptor Tie2 promoter was used (Figure 1A). Targeted 
LOX-1 gene expression in ECs was achieved using the expression vector 
pSP14/15, which contains the murine 2 kb Tie2 promoter together with a 10 kb 
Tie2 enhancer originated from intron 1 of the endogenous murine Tie2 gene (the 
pSP14/15 vector was a kind gift of Thomas N. Sato, MD, PhD, University of Texas, 
USA). The coding sequence for the murine LOX-1 tagged with FLAG sequence 
and fused with human growth hormone polyA signal by PCR amplification was 
inserted into NotI restriction site of pSP14/15 between Tie2 promoter and 
enhancer. The following primers were used to generate this fusion coding 
sequence: sense 5’-TAAGATATCGAGGTCCTCGACTGTTTCAG-3’ (contains 
EcoRV restriction site on its 5’-end (bold underlined), and the sequence 
corresponding to murine LOX-1 cDNA (bases 12-31 of OLR1 cDNA; NCBI no. NM 
138648)) and antisense 5’-
GCCAAGCTTTCACTTGTCATCGTCGTCCTTGTAGTCAATTTGCAAATGATTTGT
CTTCTTC-3’ (contains HindIII restriction site on its 5’-end (bold typed and 
underlined), the sequence for FLAG-tag (italic), and the sequence that corresponds 
to murine LOX-1 cDNA (underlined), bases 1123-1147 of OLR1 cDNA; NCBI no. 
NM 138648). The resultant targeting vector was linearized and microinjected into 
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fertilized eggs prepared from superovulated C57BL/6 mice. The eggs were 
transferred into the oviducts of pseudopregnant foster mothers. Founder mice were 
identified by PCR analysis using Tie2/LOX-1 specific pair of primers: sense 5’-
CCCTGCTGATACCAAGTGCC-3’ (corresponds to sequence from murine Tie2 
promoter region: +111 - +130 from the Tie2 transcription start) and antisense 5’-
CTTCTTTGATTCCTGTGAAGCG-3’ (bases 334-355 of OLR1 cDNA; NCBI no. NM 
138648). The presence of the transgene was further confirmed in founder mice by 
Southern blot hybridization using [32P] dCTP-labeled LOX-1-specific probe (Figure 
1B). Several lines of LOX-1 transgene in the C57BL/6 background were 
established, which carry different numbers of LOX-1 copies. To obtain LOX-1 
TG/ApoE-/- double mutant mice hemizygous LOX-1 transgenic mice, from the line 
carrying maximal number of copies of the transgene, were crossbred with 
homozygous ApoE-/- mice on a C57BL/6 background. Offspring mice, carrying 
LOX-1 transgene and being heterozygous for the ApoE locus, were further cross-
bred with homozygous ApoE-/- mice to generate LOX-1 TG/ApoE-/- double mutant 
mice. Animals were maintained on a standard western chow diet until they were 
put on a high cholesterol diet (HCD, 1.25% total cholesterol; Research Diets). They 
had free access to food and water and were kept at a 12 hours light/dark cycle. 
The homozygous mutation in the ApoE locus was proved by PCR analysis with the 
ApoE-specific primers as described. 
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RT PCR analysis 
Total RNA was extracted from aortic arches using TRIzol Reagent (Invitrogen) 
according to the manufacturer’s recommendations. Conversion of the total cellular 
RNA to cDNA was carried out with murine leukemia virus reverse transcriptase and 
random hexamers (Amersham Bioscience) in a final volume of 33 µl, using 4 µg of 
cDNA. All RT PCR experiments were performed using the SYBR Green JumpStart 
kit (Sigma).  
 
Tissue harvesting and processing 
 After puncturing the left ventricle and cutting the right atrium, vessels were 
rinsed briefly with normal saline and the aorta was excised after removing 
adventitial tissue and fat. For en face analyses, descending aortas were opened 
longitudinally. For histological examination, the aortic root was embedded in OCT 
(optimal cutting temperature) compound (Tissue-Tek; Sakura), frozen on dry ice, 
and stored at –80°C. For biochemical analyses, aortic arches were shock-frozen in 
liquid nitrogen and stored at -80°C. 
 
Plaque quantification 
 For quantification of atherosclerosis in LOX-1 TG and corresponding 
C57BL/6 wild type mice, the aortic root was embedded in OCT, Tissue-Tek; 
Sakura) and frozen in isopentane. Serial cross sections of the aortic root (8 µm 
thickness) were cut and thaw-mounted on glass slides for immunohistochemistry 
Oil red-O staining. 
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 To quantify atherosclerotic plaques in LOX-1 TG/ApoE-/- double mutant mice 
and ApoE-/-, en face analysis of the descending aorta was performed. Plaque area 
was visualized by fat staining (Oil red-O) and quantified (Analysis 5; SoftImaging 
System). 
 
Immunohistochemistry 
 Cross sections of aortas were fixed with acetone, and immunostaining was 
performed using the following primary antibodies: rat anti-mouse CD68 (Serotec), 
monoclonal rat anti-mouse CD106 (VCAM-1, Serotec), monoclonal rat anti-mouse 
P-sel (BD Pharmingen), and monoclonal rat anti-mouse CD3 (Serotec). For 
immunohistochemical detection an alkaline phosphatase–labeled donkey anti-goat 
antibody was used. Alkaline phosphatase was visualized using naphthol AS-BI 
phosphate and new fuchsin as substrate. Endogenous alkaline phosphatase was 
blocked by levamisole. Color reactions were performed at room temperature for 15 
min with reagents from Sigma. Sections were counterstained with hematoxylin, and 
cover slips were mounted with glycerol and gelatin. Negative controls included 
omission of the first antibodies and preincubation of the first antibodies with 
immunogenic peptides. Slides were mounted with Glycergel mounting medium 
(Dako) and quantified (Analysis 5; SoftImaging System). 
 
Western blotting 
 Murine aortic arches were homogenized in a lysis buffer containing 50 mM 
Tris, pH 7.5; 1 mM EDTA, pH 8.0; 150 mM NaCl; 1 mM PMSF, and 1 mM DTT. 
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Total protein extracts were cleared by centrifugation and 40 µg of proteins were 
separated by gel electrophoresis on 10% SDS-polyacrylamide gel followed by the 
semi-dry transfer onto the PVDF membrane. Finally, the membrane was incubated 
with primary goat anti-LOX-1 antibody (R&D Systems). Primary anti-GAPDH or 
anti-α-tubulin (Sigma) antibodies were used as loading controls. Secondary 
peroxidase-labelled anti-species-specific IgG antibodies (Amersham Biosciences, 
GE Healthcare Europe GmbH) were diluted 1:2500 and incubated with the 
membranes for 1 h at room temperature. Proteins were visualized after incubation 
of the membranes with Amersham™ ECL Plus Western Blotting Detection Solution 
(Amersham Biosciences, GE Healthcare Europe GmbH) for 5 min at RT. Protein 
expression was quantified using Scion Image™ software and expressed as ratio to 
corresponding loading control.  
 
Plasma lipids  
 Plasma cholesterol level was determined using Infinity™ Cholesterol 
(Thermo Electron Corporation Standard) and MC Cal (Abbott). Plasma triglycerides 
level was measured using Infinity™ Triglycerides (Thermo Electron Corporation 
Standard) and MC Cal (Abbott). The distribution of lipids within the plasma 
lipoprotein fractions was assessed by fast-performance liquid chromatography 
(FPLC) gel filtration using a Superose 6 HR 10/30 column (Pharmacia). 
 
Endothelium-dependent relaxation of intact aorta 
The thoracic aortas of ApoE-/- and LOX-1 TG/ApoE-/- mice were isolated 
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after 20 weeks of HCD. Aortas were dissected free, excised and placed into cold 
modified Krebs-Ringer solution of the following composition (mM): NaCl 118, KCl 
4.7, CaCl2 2.5, MgSO4 1.2, NaHCO3 25.0, KH2PO4 1.18 and calcium disodium 
EDTA 0.026, glucose 11.1 (control solution). The blood vessels were cut into rings 
(2 mm in length). The rings were suspended in organ chambers containing control 
solution (37°C) aerated with 95% O2 and 5% of CO2. They were connected to a 
force transductor (Powerlab Model ML785and ML119). Changes in isometric 
tension were recorded. The rings were stretched progressively to their optimal 
resting tension (0.75 g) and were allowed to equilibrate for 90 minutes. 
Concentration-response curves were obtained in a cumulative way. To study 
endothelium-depended relaxations to acetylcholine, the preparations were exposed 
to U 46619 [in order to obtain 50-70% of response to KCl (60 mM)]. Sodium 
nitroprusside (SNP) was applied to study the endothelium-independent relaxation.   
 
Isolation of murine endothelial cells 
Murine aortic ECs were isolated as described previously [31]. Briefly, 8 week old 
male mice were sacrificed by cervical dislocation. Animals were perfused via left 
ventricle puncture with 5ml of normal saline, followed by collagenase type II 
(580U/ml, dissolved in serum free DMEM, Worthington). After ligation with a silk 
thread, the thoracic aorta was removed and incubated for 45 minutes in 37oC. ECs 
were flushed with 5ml of DMEM containing 20% FBS and plated on 0.1% gelatin-
covered plates. 
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Lipid uptake 
EC or macrophages were stimulated with 10ug/ml Dil-oxLDL (Intracell). After 6 
hours cells have been harvested and stained with anti-mouse CD105 antibody 
(Pharmingen), followed by incubation with FITC-labeled anti-rat secondary 
antibody (Molecular Probes, cat no: A-11006). Mean fluorescence of CD105-gated 
cells was monitored with FACS (BD, Canto II) and analysis of the data was 
performed using FlowJo software. 
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Legends to Figures and Tables 
 
Figure 1. Generation and characterization of endothelial-specific LOX-1 TG 
mice. (A) Scheme of endothelial-specific LOX-1 transgenic construct. (B) Southern 
blot analysis of F1 generation. Genomic DNA was digested with BamHI, and 
hybridized with LOX-1-specific radioactively-labeled probe. (C) Real time PCR 
analysis. Total RNA isolated from either aorta (a) or kidney (k) of three different 
transgenic lines 5048.54, 5048.24, and 5048.1 transformed into cDNA and 
amplified with LOX-1-specific primers. (D) Western blotting of aortic lysates using 
anti-murine LOX-1 antibody. Recombinant truncated version of murine LOX-1 used 
as a positive control. (E) Aortic cross sections from C57BL/6 wild type (WT) (left) 
and LOX-1 TG (right) stained with anti-murine LOX-1 antibody. Bar = 100 µm. 
 
Figure 2. Functionality of LOX-1 construct. (A) Representative graph of the EC 
culture purity based on anti-CD105 staining. (B) Murine ECs isolated from WT and 
LOX-1 TG mice incubated with Dil-oxLDL for 6 hours, stained with an anti-mouse 
CD105 antibody. Mean fluorescence of the CD105 positive cells monitored with 
FACS; n=4. **P<0.01; unpaired two-tailed Student t-test. (C) Representative 
picture of ECs stimulated with oxLDL for 6 hours and stained with oil-red O (ORO). 
Values are expressed as mean ± SEM. 
 
Figure 3. Increased aortic fatty streak formation in LOX-1 TG mice. (A) Cross 
sections through aortic roots of WT and LOX-1 TG mice after 30 weeks of HCD 
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stained with ORO and (B) corresponding quantification. *P<0.05; unpaired two-
tailed Student t-test. Values are expressed as mean ± SEM. Bar = 100 µm.  
 
Figure 4. Increased expression of adhesion molecules and extravasation of 
macrophages in LOX-1 TG mice. Increased expression of messenger RNA for 
(A) VCAM-1 and (B) E-sel in LOX-1 TG (n=11) mice compared with WT mice 
(n=11, *P<0.05). Cross sections of aortic roots from WT and LOX-1 TG mice 
stained with (C) antibody against VCAM-1, and (E) antibody against CD68 with 
corresponding quantifications ((D) and (F) respectively); unpaired two-tailed 
Student t-test. Values are expressed as mean ± SEM. Bar = 100 µm. 
 
Figure 5. Increased aortic plaque formation in LOX-1 TG/ApoE-/- mice. (A) En 
face ORO staining of descending aortas of ApoE-/- or LOX-1 TG/ApoE-/- mice after 
20 weeks of HCD. (B) Increased atherosclerotic burden in LOX-1 TG/ApoE-/- mice 
compared with ApoE-/- controls (n=9-12, *P<0.05) mice; unpaired two-tailed 
Student t-test. Values are expressed as mean ± SEM. 
 
Figure 6. Enhanced VCAM-1 and P-sel expression in LOX-1 TG/ApoE-/- mice. 
Cross sections of aortic roots from ApoE-/- or LOX-1 TG/ApoE-/- mice stained with 
(A) antibody against VCAM-1 with corresponding quantification (B; n=7; *P<0.05). 
(C) Increased expression of messenger RNA for VCAM-1 in LOX-1 TG/ApoE-/- 
mice compared with ApoE-/- mice (n=13, *P<0.05). Cross sections of aortic roots 
from ApoE-/- or LOX-1 TG/ApoE-/- mice stained with (D) antibody against P-sel with 
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corresponding quantification (E; n=9; **P<0.01); unpaired two-tailed Student t-test. 
Values are expressed as mean ± SEM. Bar = 100 µm. 
 
Figure 7. Increased extravasation of macrophages and lymphocytes in LOX-1 
TG/ApoE-/- mice. Cross sections of aortic roots from ApoE-/- or LOX-1 TG/ApoE-/- 
mice stained with (A) antibody against CD68, or (C) antibody against CD3 (arrows 
indicate positive staining) with corresponding quantifications ((B) and (D) 
respectively). *P<0.05; unpaired two-tailed Student t-test. Values are expressed as 
mean ± SEM. Bar = 100 µm. 
 
Table 1. Plasma lipid levels. 
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9. Discussion of the results  
 
The aim of this thesis was to find and characterize new genes involved in 
the pathogenesis of atherosclerosis. We studied several molecules, which could 
be relevant for different aspects of disease development, namely: (i) histamine 
receptors, which are well known mediators of inflammatory response [12, 66, 67], 
(ii) L-sel, an adhesion molecule responsible for early interactions between 
leukocytes and activated endothelium [18, 28], and (iii) LOX-1, a scavenger 
receptor for oxLDL expressed by ECs [41]. Genetically modified mice were used 
to assess the importance of these molecules in atherosclerosis development. 
 
“Histamine H1 receptor promotes atherosclerotic lesion formation by 
increasing vascular permeability for low density lipoproteins” 
Histamine was demonstrated to regulate several processes affecting 
atherosclerosis development in vitro, such as expression of adhesion molecules, 
and proinflammatory cytokines, Th1/Th2 balance and vascular permeability [12, 
68]. However, the relevance of histamine-mediated signalling in atherogenesis in 
vivo remained unclear. We demonstrated for the first time that both 
pharmacological blockade and genetic deletion of H1R, but not H2R, attenuates 
the development of atherosclerosis in ApoE-/- mice. Genetic deletion of H1R 
displayed a more pronounced effect on atherosclerosis development compared 
to pharmacological blockade (60% versus 40% of atherosclerotic plaque 
reduction). This may well be related to a lower efficiency of the pharmacological 
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inhibition compared to the genetic approach. Indeed, it is to be expected that 
pharmacological blockade of a receptor in vivo can not be complete; while 
genetically modified animals do not express the receptor at all. 
Increased vascular permeability is an important consequence of ECs 
activation and leads to LDL accumulation in the arterial intima, favouring the 
formation of atherosclerotic plaques [1, 69]. Acute stimulation with histamine is 
known to increase vascular permeability in vitro as well as in vivo, particularly in 
the context of acute allergic reactions [70]. Indeed, treatment with H1R 
antagonists is a highly effective therapy against allergic diseases [71-74]. Since 
expression of HDC increases during atherosclerosis development, 
atherosclerotic plaques, but not normal arteries, contain large amounts of 
histamine [11]. The enhanced histamine concentration in the vascular wall may 
indeed affect vascular permeability chronically during atherosclerosis 
development. To address this issue, we monitored aortic permeability of ApoE-/- 
H1R-/- mice to radiolabeled LDL. Lack of H1R clearly attenuated vascular 
permeability in ApoE-/- animals. This effect was observed in animals without 
macroscopically visible atherosclerotic plaques as well as in mice with more 
advanced atherosclerosis. Indeed, neither the occurrence nor the magnitude of 
this effect depended on the stage of atherosclerosis; suggesting a primary 
difference. Consistent with this observation, the total fat content in atherosclerotic 
plaque was reduced upon H1R deletion as compared to controls. These data 
indicate that histamine acting via H1R is a critical determinant of vascular 
permeability during atherosclerosis development. In line with this interpretation, 
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bone marrow transplantation revealed that the presence of H1R on vascular 
cells, but not on BM-derived cells, promotes atherogenesis.  
ApoE-/- H1R-/- animals exhibited reduced numbers of both, macrophages 
and Th cells in atherosclerotic plaques compared to ApoE-/- mice. This was 
associated with decreased abundance of CCL5 in aorta of ApoE-/- H1R-/- mice. 
Moreover, atherosclerotic, but not normal animals, lacking the H1R exhibited 
reduced spleen weight and blood lymphocytes number. We can speculate that 
reduced local and systemic inflammation in ApoE-/- H1R-/- mice is a consequence 
of diminished aortic permeability. Indeed, it has been demonstrated that 
histamine-mediated permeability is associated with increased leukocyte 
accumulation [75]. Moreover, mmLDL may act like chemoattractant [1]; thus, 
impaired accumulation of LDL could account for reduced leukocyte 
extravasation.  
To evaluate the contribution of vascular versus BM-derived cells in 
atherosclerosis development in ApoE-/- H1R-/- mice, BM transplantation was 
performed. This experiment revealed that the presence of H1R on vascular, but 
not bone marrow-derived cells, promotes atherosclerotic plaque formation. These 
data support the interpretation that differences in inflammation in animals lacking 
H1R are secondary to reduced vascular permeability in these animals. 
In conclusion, this study demonstrates that H1R, but not H2R, is crucially 
involved in atherosclerosis, most likely due to its role as a mediator of vascular 
permeability. However, we did not discriminate between vascular permeability 
and LDL retention in the vessel wall, which could be an alternative explanation of 
  47
decreased vascular LDL abundance in animals lacking H1R. A long-term in-vivo 
permeability assay as well as studies demonstrating the exact location of the LDL 
within atherosclerotic plaque of animals lacking the H1R is required to address 
these questions. 
 
“Accelerated early atherosclerosis in mice deficient in L-selectin” 
Atherosclerosis is a result of the chronic inflammation induced by 
accumulation of cholesterol and leukocytes into the arterial intima [1]. L-sel 
belongs to selectin family of adhesion molecules regulating initial stages of 
leukocytes extravasation [18, 28]. Therefore, we hypothesize that L-sel deletion 
reduces atherosclerosis development due to reduction in leukocyte migration into 
atherosclerotic plaques. To test this hypothesis we generated ApoE-/- L-sel-/- and 
compared them to ApoE-/- controls during early (no HCD, 6 weeks of HCD) and 
more advanced (12 weeks of a HCD) stages of the disease. Surprisingly, we 
found that deletion of L-sel accelerates early, but not advanced atherosclerosis.  
We used intravital microscopy to monitor whether deletion of L-sel affects 
leukocyte capture and rolling during atherosclerosis development. We did not, 
however, observe any differences between ApoE-/- L-sel-/- animals and 
corresponding ApoE-/- controls. These results are in line with some previous 
reports which describe overlapping function for all selectin family members [40, 
76]. Moreover, most of the studies describing the importance of L-sel in leukocyte 
rolling along activated endothelium focused on venules and arterioles [30, 77], 
whereas atherosclerosis is a disease of large arteries. Finally, some studies were 
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performed under different experimental conditions, for example after adaptive 
transfer, which may affect the activatory state and intrinsic properties of 
transferred leukocytes [39]. In line with this finding, we did not detect any 
difference in cellular composition of atherosclerotic plaques. Indeed, plaque 
morphology, number of macrophages and T-cells accumulated into plaques were 
similar in ApoE-/- L-sel-/- and ApoE-/- mice. 
As described previously, L-sel deficient mice exhibited altered leukocyte 
distribution due to defective lymphocyte homing to peripheral lymph nodes [28]. 
Indeed, we observed significantly decreased size and cellularity of lymph nodes, 
increased numbers of blood lymphocytes, and compensatory increase in spleen 
size. This alteration occurred independently from the stage of atherosclerosis 
development, thus it cannot explain the difference in atherosclerosis 
development. 
In summary, this study demonstrates the complexity of the immune 
response during atherosclerosis development. We showed that L-sel deletion 
results in leukocyte redistribution and acceleration of early, but not advanced 
atherosclerosis. We suggest that L-sel deletion results in very complex changes 
in the immune system affecting atherosclerosis. The mechanism of this 
phenomenon, however, remains unclear and requires further investigation. 
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“Endothelial overexpression of lectin-like oxidized low-density lipoprotein 
receptor-1 (LOX-1) increases aortic LDL uptake and plaque formation in 
vivo” 
One of the important mechanisms of ECs activation and dysfunction is 
associated with the uptake of modified LDL particles [13, 44]. ECs activation 
precedes formation of atherosclerotic changes and is an important event in early 
atherogenesis [78]. While macrophages migrated into the vessel wall scavenge 
oxLDL using SR-A and CD36, ECs take up oxLDL mainly via LOX-1 [13, 41, 49]. 
Indeed, it has been demonstrated in vitro that oxLDL uptake initiates a cascade 
of molecular events leading to ECs activation [13].  
We have generated transgenic animals overexpressing LOX-1 specifically 
in the ECs. We studied these animals in the context of early atherosclerosis after 
30 weeks of HCD. In addition, we crossed bred these mice with ApoE-/- animals 
and fed them for 20 weeks a HCD to monitor the relevance of LOX-1 in 
advanced atherosclerosis. Recently, it has been demonstrated that animals 
lacking LOX-1 exhibit decreased atherosclerotic burden [57]. In line with this 
finding, LOX-1 overexpression accelerated both, early and advanced 
atherosclerosis, which was associated with impaired endothelium-dependent 
relaxation to acetylcholine.  
It was demonstrated that oxLDL uptake by ECs results in enhanced 
adhesion molecules expression [13]. Indeed we observed increased expression 
of VCAM-1 and E-sel in LOX-1 TG mice as well as VCAM-1 and P-sel in LOX-1 
TG/ApoE-/- mice as compared to corresponding controls. The discrepancy 
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between LOX-1 TG and LOX-1 TG/ApoE-/- mice in the expression pattern of 
adhesion molecules is not surprising, considering the different stage of disease 
development in these animals [79]. In line with this, we found increased 
accumulation of macrophages in atherosclerotic plaques of both LOX-1 TG and 
LOX-1 TG/ApoE-/- mice.  
In conclusion, in this study we showed that endothelial overexpression of 
LOX-1 is associated with increased atherosclerosis development due to 
enhanced endothelial dysfunction. However, we did not dissect the molecular 
pathways connecting LOX-1 overexpression with endothelial dysfunction. It was 
demonstrated in vitro that NFκB is involved in oxLDL-mediated ECs activation; 
however, additional studies are required to prove this observation in vivo.  
 
We believe that these novel observations improve the current 
understanding of the pathogenesis of atherosclerosis. In addition, they have 
potential therapeutic implications, since (i) histamine receptor blockers are widely 
used to prevent or treat the acute increase in vascular permeability during 
allergic reactions. Furthermore, (ii) development of strategies targeting early 
events in atherogenesis, such as endothelial activation or leukocyte capture, may 
open new therapeutic approaches for the prevention as well as for the treatment 
of atherosclerosis. 
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